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1. INTRODUCTION 
 
 
1.1. Migraine: epidemiology and pathophysiology 
Headaches are the most common painful syndromes in the young-middle age, 
affecting people’s quality of life and causing a significant economic impact. 
Among primary headaches, migraine is the most common and disabling one, 
affecting about 15% of the population of North America and Western Europe. 
Since migraine was first included in the Global Burden of Disease study (GBD), 
which represents the most comprehensive worldwide observational epidemiological 
study to date, it has ascended the ranks of top causes of disability worldwide. 
In the recent publication of 2016, in the age group of 15–49 years, migraine is the 
top cause of disability. 
Even though a comprehensive knowledge of migraine pathophysiological 
mechanism is still lacking, many efforts have been done, in the last decades, to 
disentangle the complicated puzzle of migraine pathophysiology with the help of new 
research tools, as neurophysiological and modern neuroimaging technologies.  
Clinical neurophysiology methods are non-invasive techniques that allow in vivo 
measurements of cortical excitability and electrocortical responses to various 
sensory stimuli and to deepen our knowledge on cortical plasticity in healthy subjects 
and in migraine patients.   
Progresses in headache research were also favoured by the introduction of the 
International Classification of Headache Disorders (ICHD) and its revisions, because 
detailed diagnostic criteria allowed to perform better comparison of clinical and 
neurophysiological data between headache centres.  
Migraine is considered a neurovascular disorder, where the trigemino-vascular 
system plays a central role. Neurogenic inflammation in meningeal trigeminal 
afferents that innervate the dural vasculature is characterized by the release of 
neuropeptides (substance P, calcitonin gene related peptide), leading to vasodilation, 
plasma extravasation and mast cell degranulation. These sensitized trigeminal 
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afferents, with their cell bodies located in the trigeminal ganglion, project to the 
trigeminal nucleus caudalis in the brainstem, which in turn projects to higher brain 
centers. 
Indeed, together with the trigemino-vascular system, the brainstem, the 
thalamus and the cerebral cortex are also involved in migraine pathophysiology as 
main actors. In particular, abnormal thalamic pacemaker rhythmic activity, namely 
“thalamo-cortical dysrhythmia” could be responsible for a low level of cortical 
preactivation in the sensory cortices. 
Since episodic migraine is characterized by recurrent clinical attacks separated by 
variable-length headache-free intervals, several studies have focused on ictal versus 
interictal electrophysiological abnormalities. They showed that migraine brain 
exhibits, if compared to healthy subjects, interictal dysfunctions of the central 
nervous system. Such dysfunctions probably represent the neurophysiological 
substrate of the clinical predisposition to attack recurrence.  
This predisposition is the “core” of migraine disease and is genetically 
determined, with environmental factors that may act as triggers. 
Furthermore, chronic migraine, defined as headache occurring on at least 15 days 
per month for more than 3 months, behaves from a neurophysiological point of view, 
like a “never ending migraine attack”. Consequently, the exploration of 
neurophysiological disfunctions in migraine could help defining and understanding 
the mechanisms involved in migraine pathophysiology and chronification. 
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1.2. Habituation and sensitization in migraine 
Since migraine is characterized by a dysfunction in sensorial information processing, 
studying the cortical responses to sensory stimulation, particularly in interictal phase, 
could help defining the neurophysiological markers of migraine brain, and probably 
understanding the mechanisms underlying predisposition to attack recurrence and 
chronification. 
Habituation is defined as a decremental response to repeated sensory 
stimulations (Harris, 1943) and represents a physiological response observed in a 
wide range of neuronal circuits, allowing to control the signal-to-noise ratio 
generated by sensory stimuli and to orientate human response to environmental 
modifications. 
According to the “dual-process” theory (proposed in the 70's by Groves and 
Thompson), during a sequence of repetitive stimuli, two opposing processes compete 
to define the final response: sensitization and habituation. The first one is prevalent 
in the initial part of the stimulus session, causing a transitory increase in response 
amplitude, while the second one occurs in the following phase and accounts for the 
delayed response decrement. 
Habituation is a physiological response that protects the cortex against the risk of 
inward information overflow, while preparing brain networks to adequately respond 
to subsequent relevant stimuli.  
Since habituation may be considered a basic form of learning (Thomson et al, 
1966; Chung et al, 2002), the phenomenon of habituation is useful for studying the 
mechanisms of information processing and learning within the central nervous 
system and, ultimately, the neuronal substrates of behaviour. 
Habituation of the evoked potentials can be assessed by averaging successive 
blocks of responses. Migraineurs are interictally characterized by a “deficient 
habituation”, meaning that they show, instead of a physiological decrease 
(habituation), an amplitude increase of scalp-evoked potentials to repeated 
stereotyped stimuli.  
This phenomenon was reported in migraine patients for almost all sensory 
modalities: visual (Schoenen et al, 1995), auditory (Ambrosini et al, 2009), 
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somatosensory (Ozkul et al, 2002) and painful stimuli (Valeriani et al, 2003; de 
Tommaso et al, 2005). Nevertheless, it was also reported for cognitive stimulations 
(Kropp et al, 1995). 
Interestingly, the habituation deficit may have a familiar character and was 
proposed as a neurophysiological marker for migraineurs (Siniatchkin et al, 2001) and 
asymptomatic subjects at risk of developing the disorder (Di Clemente et al, 2007). 
Besides the lack of habituation, evoked potentials in migraineurs are 
characterized by a low amplitude of the first block of averagings (for a review see 
Ambrosini et al, 2003), ruling out the theory that the habituation deficit in migraine 
could be due to cortex hyperexcitability. These data support the hypothesis of an 
interictal reduced pre-activation level of sensory cortices, possibly due to insufficient 
activation by aminergic projections from the upper brainstem (Schoenen et al, 1996) 
and, consequently, a dysfunction in thalamo-cortical drive, known as “talamo-cortical 
dysrhythmia” (Llinas et al, 1999; Coppola et al, 2007). 
Therefore, the heightened response to repeated stimuli (or habituation deficit) in 
migraineurs is the consequence of sensory cortices “hyperresponsivity”, which 
results in an exaggerated energy demand and, possibly, in subtle cognitive 
dysfunctions (Magis et al, 2007). 
However, habituation is not a static phenomenon but fluctuates over time in 
relation to the migraine cycle. In particular, the habituation deficit reaches its 
maximum during the days preceding the attack, while increases and normalizes 
immediately before and during the attack, when the thalamo-cortical drive also 
increases (Coppola et al, 2005). Such fluctuation is probably related to changes in 
serotonin transmission, which is low interictally (Panconesi et al, 2008) and may 
increase ictally. 
On the other side, sensitization, defined as facilitation occurring at the beginning 
of the stimulus presentation, was evidenced during the attack, especially with 
somatosensory stimuli (as reflected by a significant increase in SSEP 1st N20-P25 
block amplitude), while disappeared between attacks (Coppola et al, 2010). 
Sensitization was evidenced also in chronic migraine with and without medication 
overuse. However, in chronic migraine without drug overuse a normal habituation 
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was found for visual evoked responses (Chen et al, 2011; Schoenen et al, 2011), while 
in medication overuse headache (MOH) a deficient habituation was found for 
somatosensory evoked potentials (Coppola et al, 2010).  
Therefore, cortical sensitization and hyperresponsiveness (Coppola et al, 2010; 
Currà et al, 2011) could be considered neurophysiological markers of MOH. 
The neural network underlying habituation is poorly understood. Consequently, 
the deficient habituation, even representing the most reproducible abnormality of 
evoked potentials detectable during the pain-free interval in migraineurs, still lacks a 
conclusive interpretation. 
Relevant information on the pathophysiology of the interictal dysfunction in 
migraine came from studies of the high-frequency oscillations (HFOs) embedded in 
somatosensory and visual evoked potentials. Early somatosensory HFOs, reflecting 
spike activity in thalamo-cortical drives, were shown to decrease in interictal 
migraineurs and to normalize during the attack, while a significant habituation deficit 
of the late visual HFOs was observed in the interictal phase, demonstrating a 
dysfunction in cortical oscillatory networks, reflected by an abnormal thalamic  
rhythmic activity, named “thalamo-cortical dysrhythmia” (Coppola et al, 2007). 
Several biochemical and neuroimaging studies suggested that the habituation 
deficit could be related to modifications in serotonin transmission, which fluctuate 
during the migraine cycle (Ferrari et al, 1993, Evers et al, 1999), reflecting 
dysfunctions in monoaminergic nuclei activity and activation of the 
pontomesencephalic areas of the brainstem during migraine attacks (Weiller et al, 
1995; Bahra et al, 2001). 
Futhermore, the serotonergic system is presumably affected by the chronic use 
of medications, determining neuronal hyperexcitability and trigeminal activation in 
patients affected by MOH (Srikiatkhachorn et al, 2000; Dobson et al, 2004). 
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1.3. Motor cortex excitability in migraine 
Impairment of mechanisms regulating the responsivity to various stimuli is a hallmark 
of migraine brain.  Although the mechanisms underpinning brain “dysexcitability” are 
still debated, there is general agreement that such abnormalities widely affect 
subcortical areas and likely the whole cerebral cortex. 
Therefore, besides studying sensory processing in migraine patients, great effort 
was also made to characterize motor cortex excitability in migraine. 
Cortical excitability of the motor cortex can be examined using transcranial 
magnetic stimulation (TMS) over the motor cortex and then recording the evoked 
peripheral activity from a muscle, namely the motor-evoked potentials (MEPs). TMS 
is a non-invasive technique that is used worldwide both in clinical practise, to assess 
the conduction of the descending cortico-nuclear and cortico-spinal pathways, and 
for neuroscientific purposes. Indeed, changes in motor activation and excitability can 
be easily assessed by recording MEPs (for a review see Rossini et al, 2015). 
Neurophysiological measures, such as corticomotor threshold (MT), MEP amplitude 
and latency, Cortical Silent Period (CSP) duration, Central Motor Conduction Time 
(CMCT) can be used to provide evidence of pathological changes in motor cortical 
control or corticospinal output in patients. 
Corticospinal excitability can be estimated by measuring the cortical motor 
threshold (or resting motor threshold, RMT), which is the minimal intensity of motor 
cortex stimulation required to elicit a MEP of minimal amplitude in a relaxed target 
muscle. The MEP size can be estimated by measuring the peak-to-peak amplitude 
after setting the stimulation intensity at 115-125% of the individual’s RMT. 
Intestingly, studies regarding motor cortex excitability in migraine patients 
reported controversial findings. In particular, resting motor threshold in interictal 
migraine were reported to be normal (Werhahn et al, 2000), increased (Afra et al, 
1998) or reduced (van der Kamp et al, 1996).  
A recent neurophysiological study didn’t find any difference in RMT between 
interictal migraineurs and controls but, by exploring the effect of a first conditioning 
stimulus on the motor evoked potential (MEP) elicited by a second test stimulus, 
modifications in short-term intracortical inhibition and facilitation mechanisms 
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according to the migraine cycle (ictal, interictal, pre-ictal) were disclosed. Indeed, 
they found decreased short-interval intracortical inhibition (SICI) in interictal 
migraineurs when compared to healthy controls, a shortened CSP only in female 
interictal migraineurs and a decreased ICF in pre-ictal compared to interictal 
migraineurs (Neverdahl et al, 2017). 
Furthermore, intracortical excitability was found to be variable in relation to the 
intensity of stimulation, indicating that different neuronal circuits can show different 
activation and inhibition thresholds: an increased ICF was found in migraineurs, as 
compared to the healthy subjects, only by using a 110% intensity of the test stimulus 
(Cosentino, 2018). Anyway, neither in this case, the authors found any differences 
between interictal migraineurs and controls as regards RMT (Cosentino et al, 2018). 
That probably happened because motor cortex excitability is not a static 
parameter. As happens for habituation in sensory cortices, motor cortex excitability 
may fluctuate according to the migraine cycle and, within interictal phase, according 
to the time interval from the last ictal phase. 
Indeed, we recently found that motor cortex excitability (MEP threshold and 
amplitude) in interictal migraineurs varies on the basis of the time elapsed since the 
last attack: RMT is lower when long time interval has passed after an attack and is 
higher when measured close to an attack (Cortese et al, 2017). Such dynamic RMT 
variations in relation to the migraine cycle represent time-dependent plastic changes 
in brain excitability that resemble those occurring for visual and somatosensory 
evoked potentials.  
Several neurophysiological studies failed to disclose significant differences in 
motor cortex excitability (in terms of RMT, latency and first MEP size) between 
chronic migraine patients, healthy subjects and episodic migraineurs (Cosentino et 
al, 2014; Cortese et al, 2018; Ozturk et al, 2002). That means that basal MEP 
amplitude in chronic migraine is not different from healthy subjects, but it doesn’t 
exclude dysfunctions in motor cortex plasticity, as will be discussed later. 
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2. CHRONIC MIGRAINE 
 
 
2.1. Clinical aspects of chronic migraine 
Chronic migraine is a disease characterized by a deep impact on patients’ life (see 
May et al, 2016), with considerable disability rates and burden of disease. Chronic 
migraine, if compared to episodic migraine, has a more profound impact on 
socioeconomic functioning and quality of life (Buse et al, 2012; Blumenfeld et al, 
2011). 
Impressively, about 25% of patients with chronic migraine report a very severe 
headache-related disability, as defined by the Migraine Disability Assessment Scale 
(also known as MIDAS). That brings to reduced household and family activities and 
high direct costs (related to healthcare and therapies) and indirect costs (due to 
absenteeism from work and reduced productivity) (Bigal et al, 2008; Munakata et al, 
2009). 
According to the current diagnostic criteria of the International Classification of 
Headache Disorders (ICHD‑3 beta), chronic migraine is defined as headache occurring 
on at least 15 days per month for more than 3 months, fulfilling, at least 8 headache 
days per month, the criteria for migraine headache (Headache Classification 
Committee of the HIS, 2013). Noticeably, in contrast to earlier classification editions, 
analgesic overuse is no longer an exclusion criterion for the diagnosis of chronic 
migraine. Consequently, according the new criteria, patients with medication 
overuse should be considered as affected by both chronic migraine and medication 
overuse headache (MOH). 
The prevalence of chronic migraine is about 1–2% in the general population, with 
three times higher prevalence in women than in men (Buse et al, 2012). 
Primary chronic migraine is rare; usually chronic migraine usually evolves from 
episodic migraine with an annual progression rate of about 3% (Scher et al, 2003). 
Risk factors for migraine chronification are: age, female sex and low educational 
status (among the non-modifiable risk factors) and overuse of acute migraine 
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medication (Bigal et al, 2008), ineffective acute treatments (Lipton et al, 2015), 
obesity and insulin-resistance (Peterlin et al, 2010; Fava et al, 2014), depression 
(Ashina et al, 2012), and stressful life events (Scher et al, 2003) (among the potentially 
modifiable factors). 
Probably the most important risk factor for migraine chronification is the overuse 
of acute migraine medication. Medication overuse headache (MOH) represents a 
relevant social burden, affecting around 63 million people worldwide (Kristoffersen 
et al, 2014). The prevalence of MOH in general population is between 1 and 2% 
(ranging from 0,5% and 7,2% in different countries), affecting mostly middle-aged 
adults from age of 30 to 50 years, with higher prevalence in studies from headache 
specialist centers, ranging from 30% to 50% of patients (Westergaard et al, 2014; 
Munksgaard et al, 2014). The majority of studies reports higher incidence in females 
with a male-to-female ratio of around 1 to 3–4 (Kristoffersen et al, 2014). 
MOH consists of a complication of a pre-existing headache syndrome and is 
characterized by overuse of one or several types of acute painkilling medications as 
simple analgesics, combination-analgesics, ergots, triptans and opioids. The diagnosis 
is based on headache frequency (equal to or greater than 15 days/a month) and 
overuse of headache medications on more than 10 or 15 days per month, depending 
on the drug class, for more than 3 months. Noticeably, migraine is the most common 
pre-existing headache disorder. 
Medication overuse discontinuation leads to reduction of headache frequency, 
facilitating prophylactic therapy effectiveness. 
Even though MOH usually resolves once the overuse is stopped (Manzoni et al, 
2015), it is no longer a requirement for the diagnosis to be made. 
The risk of chronification depends on the type of used drug, with lower risk for 
triptans and ergotamine, if compared to analgesics and opioids (Thorlund et al, 2016). 
The most important risk factors associated to the development of MOH are: 
regular use of benzodiazepines, depression, physical inactivity, smoking, age younger 
than 50, female gender and low level of education (Hagen et al, 2011). Furthermore, 
an increased risk of developing MOH was detected if a family history of MOH or other 
substance abuse was present (Cevoli et al, 2009). 
  12 
Indeed, genetic polymorphic variants in genes of the dopaminergic system and 
genes related to drug-dependence pathways have been described as potential risk 
factors for excessive use of acute medications and consequent development of MOH 
(Cargnin et al, 2017). 
Patients affected by MOH often show multiple psychiatric comorbidities. Anxiety 
and depression are the most frequently described (Lampl et al, 2016). An association 
was also found between MOH and greater susceptibility to drug dependency and 
with clinically relevant obsessive-compulsive disorder (Sarchielli et al, 2016). A high 
prevalence of sleep complaints, including insomnia, daytime sleepiness, and snoring 
was also reported (Sancisi et al, 2010) in MOH patients. 
Various respiratory and cardiovascular conditions more likely coexist with chronic 
migraine than with episodic migraine (Buse et al, 2010). 
Anyway, protective factors, such as physical exercise, stress management, and 
preventive medications, may help reducing the frequency of migraine attacks, 
thereby reducing the risk of migraine chronification. 
Withdrawal of acute painkilling drugs is the first-line approach for the 
management of MOH patients. 
A recent randomized clinical trial showed that complete discontinuation of acute 
medications is the most effective strategy (if compared to restricted medications 
intake) (Carlsen et al, 2018). 
Withdrawal can be quite difficult for some patients because of the frequent 
appearance of withdrawal symptoms as headache, nausea, vomiting, anxiety, sleep 
disturbances, that usually last for 2–10 days and can be very disturbing. 
The choice of the setting for withdrawal (inpatient or outpatient withdrawal) 
should consider several factors, including the type of overused medications, the 
duration of the overuse, the possible history of previous detoxification failures or 
psychiatric comorbidities. 
In clinics, a standardized therapeutic protocol for medication withdrawal is 
lacking. 
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Several strategies are commonly used such as intravenous hydration, rescue 
medications (different from overused drugs), antiemetics, benzodiazepines, and 
sometimes corticosteroids. 
Special reference needs to be made about prophylactic treatment.  
Discussion between the three main options is still going on: some authors 
advocate withdrawal of acute medication alone, others suggest early prophylaxis 
alone, and a third group stands for withdrawal in combination with early prophylaxis 
(Rossi et al, 2009). 
Although evidence-based recommendation for MOH treatment is not possible for 
the lack of randomized controlled trials, there is currently more evidence for 
discontinuation of acute medication overuse, or tapering plus early prophylaxis, than 
for withdrawal alone (Chiang et al, 2016).  
Anyway, what we know for sure is that a successful detoxification leads to a better 
response for preventive treatments, even in patients with little improvement in 
headache frequency after withdrawal (Zeeberg et al, 2006). 
There are various prophylactic treatment options for chronic migraine. Standard 
pharmacological treatment includes topiramate, which has been investigated in 
more than one double-blinded RCTs (Diener, 2007; Silberstein, 2009), but also 
candesartan (Stovner et al, 2013), amitriptyline (Magalhães et al, 2010), sodium 
valproate (Yurekli et al, 2008), gabapentin (Spira et al, 2003) and tizanidine (Saper et 
al, 2002). 
Botulinum neurotoxin A (BoNT-A) is specifically approved for chronic migraine. In 
two large-scale phase III RCTs, called Phase III Research Evaluating Migraine 
Prophylaxis Therapy (PREEMPT) 1 and 2, BoNT‑A at a dose of 155-195 U, was shown 
to reduce the number of headache days in chronic migraine patients with or without 
acute medication overuse (Aurora et al, 2010; Diener et al, 2010). 
Non-pharmacological therapies include biofeedback, manual therapy, stress 
management, neuromodulatory techniques. Neuromodulatory methods can target 
peripheral nerves or specific areas in the central nervous system. Among peripheral 
neuromodulation methods, the most frequently used are: pharmacological blockade 
of the greater occipital nerve (Saracco et al, 2010) and electrical stimulation of 
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occipital nerves (Dodick et al, 2015), supraorbital nerves (Schoenen et al, 2013; Hann 
et al, 2013); or the vagal nerve (Straube et al, 2015; Kinfe et al, 2015). Transcranial 
magnetic stimulation (TMS) (Shehata et al, 2016) and transcranial direct current 
stimulation (tDCS) (Antal et al, 2011; Andrade et al, 2017) are used to achieve central 
neuromodulation. 
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2.2. Cortical plasticity in chronic migraine 
Animal studies, genetic studies, structural and functional neuroimaging, and 
neurophysiological examinations have been carried on to disclose some aspects of 
chronic migraine pathophysiology, which is far from being completely understood. 
Dysfunction of the descending pain-modulating network (Bigal et al, 2008) and 
central sensitization probably play a central role in migraine chronification. 
Some evidences support the hypothesis of a persistent dysfunction in the 
periacqueductal gray (PAG) in chronic migraine, likely caused by repeated migraine 
attacks (Welch et al, 2001). 
Accordingly, disrupted functional connectivity between the PAG and brain regions 
primarily involved in nociception, somatosensory processing, emotion processing, 
and pain modulation was shown in animal models (Zihihua et al, 2017).  Furthermore, 
atypical resting state functional connectivity of affective pain processing brain 
regions was evidenced in patients affected by chronic migraine (Todd et al, 2013). 
Overall, neurophysiological and imaging studies seem to indicate that chronic 
migraine behaves like a “never ending migraine attack”. Indeed, the pattern of 
brainstem activation was found to be similar to that observed during an attack in 
episodic migraine (Aurora et al, 2007) and evoked potentials studies indicate an 
increased cortical excitability of somatosensory and visual cortex (Coppola et al, 
2010; Chen et al, 2011). Accordingly, using a method called magnetic suppression of 
perceptual accuracy (MSPA), decreased activity of inhibitory cortical interneurons, 
reflected in the smallest suppression index, was found in chronic migraine patients, 
if compared to episodic migraineurs and healthy controls (Aurora et al, 2007). 
Increased evoked responses were found also after noxious stimulations: 
increased laser-evoked potential (LEP) amplitude (de Tommaso et al, 2003) and pain-
related evoked potentials (PREPs) amplitude after electrical cephalic and 
extracephalic stimulation (Ayzenberg et al, 2006) were observed in chronic migraine 
patients.  
Hence, chronic migraine is characterized by sensitization of sensory cortices, as 
reflected by an increased response amplitude to single or low numbers of non-
noxious and noxious stimuli. 
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The clinical manifestation of central sensitization is probably represented by 
cutaneous allodynia, that occurs transiently during migraine attacks in episodic 
migraine, while is more persistent in chronic migraine (Lovati et al, 2008). 
Interestingly, habituation (defined as a decrease in average response amplitude 
after high numbers of stimuli) was found to be normal in chronic migraine in the 
visual cortex (Chen et al, 2011), while a deficient habituation was shown in patients 
with MOH, at least in the somatosensory cortex (Coppola et al, 2010). 
The differences in habituation between the two groups of chronic migraineurs 
(with and without medication overuse) are probably related to the different 
mechanism of migraine chronification.  
In MOH patients, migraine chronification is the consequence of the effects of the 
prolonged overuse of drugs on the brain. Indeed, the increased SSEP amplitude in 
MOH was found to be proportional to the duration of headache chronification 
(Coppola et al, 2010). 
The serotonergic system is presumably affected by the chronic use of 
medications, resulting in neuronal hyperexcitability, enhanced cortical spreading 
depression and trigeminal activation (Srikiatkhachorn et al, 2000; Dobson et al, 2004).  
Interestingly, chronic migraine and MOH patients exhibit similar phenotype, 
similar response to single or low number of stimuli (cortical sensitization), but 
different adaptation to repetitive stimuli (normal habituation for CM and deficient 
habituation for MOH). 
Furthermore, a progressive normalization of sensory processing after 
detoxification during follow-up was demonstrated (Munksgaard et al, 2013). This 
adds to the importance of detoxification to favour not only a clinical improvement 
but also the reversal of electrophysiological abnormalities of MOH. 
Since sensory cortices are strictly interconnected with other cortical and 
subcortical structures, several neurophysiological and neurofunctional imaging 
studies tried to shed light on the complex balance between excitatory and inhibitory 
networks in the whole brain in chronic migraineurs. 
A magnetoencephalography (MEG) study on a pediatric population showed an 
aberrant brain activation during a simple motor task (Leiken et al, 2016). The authors 
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found significantly prolonged latencies of movement-elicited magnetic fields in 
chronic migraine and relevant spatio-temporal and spectral differences between 
chronic and acute migraine, with a significant increase of brain activation in chronic 
migraine also in the ipsilateral sensori-motor cortices and deep brain areas. This 
finding indicate that chronic migraine is characterized by the recruitment of an 
abnormally large neural network for a basic motor task, indicating aberrant neural 
activation in both cortical and subcortical structures. 
A PET study showed that MOH patients exhibit significant metabolic reductions in 
thalamus and an increased metabolism in middle temporal gyrus and insula relative 
to chronic migraineurs without medication overuse (Di et al, 2013). 
Accordingly, a hypometabolism of the bilateral thalamus, orbitofrontal cortex 
(OFC), anterior cingulate gyrus, insula/ventral striatum and right inferior parietal 
lobule was found in MOH, with a following recovery to normal metabolism after 
withdrawal of analgesics, for all dysmetabolic areas except the OFC (Fumal et al, 
2006). 
Hence, several regions involved in pain processing networks were hypometabolic 
during medication overuse but recovered to normal metabolism after painkilling 
medications withdrawal, except for the OFC, whose dysfunction is linked with drug 
dependence and addiction. This region remained hypometabolic after successful 
detoxification, thus implying a potential causal role (Fumal et al, 2006). 
Exploring motor cortex excitability Ozturk and coworkers found no differences in 
thresholds, latencies and amplitudes of motor evoked potentials between chronic, 
episodic migraine and controls, while, exploring cortical inhibitory circuits by 
measuring the TMS-induced cortical silent period (CSP), they observed longer 
duration of the cortical silent period (CSP) in CM patients, being significantly different 
from both other groups (Ozturk et al, 2002). 
Another neurophysiological study on MOH patients revealed a normal CSP 
duration of the facial muscles in the whole group of MOH patients. Nevertheless, a 
subgroup analysis revealed that CSP duration was different according to the 
headache medication overused, with longer duration for patients overusing NSAIDs 
(Currà et al, 2011). 
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This finding of different neurophysiological effects depending on the overused 
drug, support the hypothesis of a direct effect of the overused medication in 
promoting plastic modifications in brain networks that may facilitate migraine 
chronification. 
Taken together, the previous evidences reveal that chronic migraine and MOH 
patients, even similar from a clinical point of view, exhibit metabolic and 
neurophysiological differences that may suggest a different mechanism of migraine 
chronification.  
Furthermore, even though motor cortex excitability (in terms of RMT and MEP 
amplitude) seems to be within normal limits, some evidences point toward 
dysfunctional plastic responses. 
Indeed, studying motor cortex plasticity, a paradoxical inhibitory response was 
found after facilitatory high-frequency repetitive transcranial magnetic stimulation 
of the motor cortex in chronic migraine (Cosentino et al, 2014). The author 
hypothesized that in conditions of increased cortical excitability the rTMS trains 
induce paradoxical responses, mediated by cortical homeostatic mechanisms. 
Hypothesizing that MOH and CM, despite exhibiting a similar clinical phenotype, 
could show different plastic behaviour, probably related to different 
pathophysiological mechanisms of migraine chronification, we recently performed a 
detailed examination of short-term plasticity mechanisms of the primary motor 
cortex in CM and MOH patients, using both low- and high- frequency rTMS over the 
motor cortex. We evidenced a dysfunction in brain plasticity in patients affected by 
MOH, showing a paradoxical inhibitory response to facilitatory trains of rTMS 
(Cortese et al, 2018), thus identifying distinctive neurophysiological mechanisms 
underpinning learning and plasticity in patients with CM or MOH. 
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3. SHORT-TERM SYNAPTIC PLASTICITY IN MEDICATION OVERUSE HEADACHE 
 
 
3.1. Rationale of the study 
Withdrawal from acute medication is the first-choice strategy in the management of 
MOH patients, but the mechanisms involved in clinical improvement after 
detoxification are not clear, even though numerous structural and functional 
neuroimaging studies showed that detoxification is associated to normalization of 
gray matter volume and connectivity of several brain areas involved in pain 
processing, cognition and planning strategies.  
Since we previously found that patients affected by chronic migraine with 
medication overuse show a maladaptive plasticity of the motor cortex, with a 
paradoxical inhibitory response to facilitatory trains of rTMS (Cortese et al, 2018), we 
carried on a neurophysiological study to understand the effects of detoxication on 
motor cortex plasticity. 
In particular, we performed an rTMS study to compare short-term plasticity 
mechanisms in MOH patients before and after withdrawal from acute medications. 
We found that the dysfunctions in short term potentiation mechanisms in MOH are 
fully reversible after withdrawal, indicating that this strategy may achieve clinical 
improvement by restoring the physiological brain plasticity. This finding adds to the 
importance of starting a withdrawal treatment as early as possible in patients with 
MOH in order to facilitate normalisation of brain plasticity mechanisms. 
This study has been recently submitted for possible publication to “Neurological 
Sciences”.  
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Introduction 
The International Classification of Headache Disorders (ICHD 3) [1] defines 
medication overuse headache (MOH) as headaches occurring ≥ 15 days per month 
for a period of at least 3 months as the result of excessive intake of acute medications 
such as non-steroidal analgesic drugs (NSAIDs) and triptans. Several 
electrophysiological studies have investigated the pathophysiology of MOH and 
demonstrated that patients with MOH exhibit characteristic neurophysiological 
abnormalities. For example, patients with MOH show response sensitisation of the 
somatosensory cortex in response to different repetitive sensorial stimulations, 
demonstrated by an initial increase in the amplitude of evoked potentials [2]. 
Patients with MOH also exhibit impaired amplitude habituation, defined as the 
absence of a decrease in amplitude in response to repeated stimulation [2–4]. Since 
habituation is a basic form of learning [5], these findings suggested that patients with 
MOH experience alterations in neural plasticity and learning processes. 
We recently assessed neural plasticity in the motor cortex of chronic migraineurs 
with and without medication overuse using low- and high-frequency repetitive 
transcranial magnetic stimulation (rTMS). We found that, depending on the duration 
of overuse headache, patients did not show short-term potentiation of motor evoked 
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potentials in response to facilitatory trains of rTMS [6]. In contrast, chronic 
migraineurs without medication overuse showed normal responses to 
inhibitory/facilitatory trains of rTMS. These observations led us to hypothesise that 
medication overuse induces a dysfunctional state of brain plasticity. On this premise, 
we further speculated that medication-induced alterations in short-term plasticity 
would normalise after the discontinuation of medication overuse. 
The aim of this study was to examine responses of patients with MOH to both 
low- and high-frequency rTMS over the motor cortex before and after drug 
withdrawal in comparison to normal subjects in order to understand the 
characteristics of short-term plasticity dysfunction in MOH. 
 
Material and Methods 
Subjects 
We recruited 16 patients with de novo MOH (according to the International 
Classification of Headache Disorders III [1]) from our headache clinic. Of these, 3 
patients were excluded because they did not meet the primary inclusion criteria (see 
below). We previously published the results of rTMS studies performed on the initial 
8 patients [6] and have combined these data with data from 5 additional patients in 
order to verify the observed effect of acute medication withdrawal. Participants were 
included if they were between 18 and 65 years of age, had at least a 1-year clinical 
history of migraine, and had never completed a detoxification program before their 
first screening visit. The inclusion criteria were restricted to patients with MOH as a 
result of NSAID use only (IHCD-III code 8.2.3.2) based on a previous study 
demonstrating that these patients exhibit more pronounced sensorimotor 
abnormalities than patients overusing acute migraine medications such as triptans 
[2, 7]. Participants were excluded from the study if they had been taking regular 
medications in the previous 3 months (e.g., antibiotics, corticosteroids, 
antidepressants, benzodiazepines, or prophylactic migraine medication; 
contraceptive pills were allowed) or if they had a history of other neurological 
disorders, systemic hypertension, diabetes or other metabolic or autoimmune 
disease, or any other type of primary or secondary headache. All participants 
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received a comprehensive description of the study and provided written informed 
consent prior to participation. The study was approved by the local ethics review 
board and was conducted in accordance with the Declaration of Helsinki. 
After application of the inclusion/exclusion criteria, the final dataset comprised 
13 patients. All patients had a clear history of episodic migraine without aura (ICHD-
III code 1.1) prior to the development of MOH. With the exception of 2 patients who 
indicated the presence of mild headache (mean visual analogue scale score, 4/10), all 
patients underwent MEP recordings in a pain-free state. Recordings were performed 
at least 3 hours after the last dose of medication; because patients with MOH self-
administer acute medication in a compulsive manner, we were unable to prevent 
patients from taking medication on the day of recording. For comparison, we also 
recruited 16 healthy volunteers (HVs) with comparable distributions of age and sex 
and no personal or familial history (first- or second-degree relatives) of migraine or 
other health conditions. Neurophysiological data for these HVs were previously 
published elsewhere [6]. To avoid hormonal interference, female participants 
completed the experimental protocol between menstrual periods. All participants 
were right-handed. 
Patients with MOH underwent a 3-week standard acute medication withdrawal 
program without any prophylactic medication. After the withdrawal period, patients 
were re-evaluated using the same experimental TMS protocol. We ensured that the 
post-withdrawal recording session occurred at least 3 days before and after a 
migraine attack, as verified by telephone or email interview. 
 
TMS procedures 
During the TMS procedure, patients were seated in a comfortable armchair and 
instructed to relax with their eyes closed. TMS was delivered through a high-
frequency biphasic magnetic stimulator (MagstimRapid, The Magstim Company Ltd., 
Whitland, South West Wales, United Kingdom) connected to a figure-of-eight coil 
with a maximal output of 1.2 T. We first determined the optimal orientation and 
position of the coil (i.e., “hot spot”) over the left motor area for stimulating the first 
right dorsal interosseous (FDI) muscle. Thereafter, the resting motor threshold (RMT) 
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was identified using single TMS pulses. The RMT was defined as the minimal intensity 
required to elicit an electromyographic (EMG) response of at least 50 μV with 50% 
probability in a fully relaxed muscle. Complete relaxation of the FDI muscle was 
verified by the absence of EMG signals as determined by visual (on a monitor) and 
acoustic feedback. Because all participants were right-handed and because patients 
did not always experience the headaches on the same side, rTMS trains were 
delivered exclusively over the left motor cortex. EMG activity in the right FDI muscle 
was recorded with surface electrodes. Thereafter, 10 consecutive trains of 10 single 
pulses of TMS (stimulus intensity, 120% of the RMT; inter-train interval, 1 min) were 
delivered at a frequency of 1 or 5 Hz in 2 separate sessions (with an intersession 
interval of at least 1 week) in a randomised order. The resulting EMG signal was 
filtered (20 Hz–1 kHz) and stored on a personal computer. All recordings were 
collected during a 3-hour period in the morning between 09:00 and 12:00 by 2 
investigators (C.L. and C.C.). The 10 trains of 10 stimuli were averaged and analysed 
off-line in a blind manner by a single investigator (F.C.). Peak-to-peak MEP amplitudes 
(µV) were measured for each of the 10 responses within the train of 10 stimuli.  
 
Statistical analysis 
All data were analysed in a blinded manner by a single investigator (G.C.) using 
Statistica version 8.0 (StatSoft Inc., Tulsa, USA) for Windows (Microsoft Corporation, 
Redmond, WA, USA).  
We first checked the normality of the data distribution using the Kolmogorov-
Smirnov test. A preliminary descriptive analysis revealed that some the peak-to-peak 
MEP amplitudes within individual rTMS trains had non-normal distributions. After log 
transformation (log10[x]), all data satisfied a normal distribution (Kolmogorov-
Smirnov test, p > 0.05).  
In order to compare the baseline findings in patients with MOH (MOH-b) with 
those of HVs, we performed a repeated measures analysis of variance (rm-ANOVA) 
with “group” as the between-subject factor (HV, MOH-b) and “stimuli” as the within-
subject factor (n = 10). Moreover, as previously described [6], we calculated the slope 
of the linear regression line for all 10 stimuli using normalised data in order to quickly 
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evaluate MEP amplitude trends within trains of rTMS stimuli. Baseline slope values 
were compared using independent Student’s t-tests. Relative changes (RC) in mean 
monthly headache days and in the slope of the linear regression were assessed using 
the following formula: RC = 100 − ([MOH-a × 100] ÷ MOH-b), where MOH-a 
represents findings obtained after medication withdrawal. Electrophysiological and 
clinical variables before and after the 3-week acute medication withdrawal program 
were compared using paired Student’s t-tests. The threshold for statistical 
significance was P < 0.05. 
 
Results 
Basic clinical and neurophysiological parameters 
Complete rTMS trains of MEPs were obtained for all study participants. Baseline 
neurophysiological parameters (RMT and the 1st MEP amplitude) were not 
significantly different between groups for either condition (1 and 5 Hz rTMS) or after 
3-week withdrawal from acute medication in patients with MOH. 
 
Effects of rTMS on baseline neurophysiological parameters 
In a rm-ANOVA model using the rTMS 1 Hz MEP peak-to-peak amplitude as the 
dependent variable, there was a borderline significant main effect of stimuli (F9,243 = 
1.867, p = 0.057), but not of group (F1,27 = 0.0255, p = 0.874) or the group × stimuli 
interaction effect (F9,243 = 0.340, p = 0.961) (Figure 1, left panel). The slope of the 
linear regression of MEP amplitudes over all stimuli was not significantly different 
between groups (t = 0.490, p = 0.628) (Figure 2, left panel).  
In a rm-ANOVA model using the rTMS 5 Hz MEP peak-to-peak amplitude as the 
dependent variable, there was a significant main effect of stimuli (F9,243 = 2.367, p = 
0.014) and the group × stimuli interaction (F9,243 = 3.714, p = 0.0002) but not group 
(F1,27 = 1.029, p = 0.319) (Figure 1, right panel). The slope of the linear regression of 
MEP amplitudes over all stimuli was significantly different between groups (t = 3.803, 
p = 0.0007) (Figure 2, right panel).  
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Effects of drug withdrawal on neurophysiological and clinical parameters 
There was no significant difference in the mean slope of the linear regression of MEP 
amplitudes over all stimuli obtained in response to 1Hz rTMS before and after the 3-
week drug withdrawal period in patients with MOH (t = −0.810, p = 0.937) (Table 2). 
In contrast, there was a significant difference in the mean slope of the linear 
regression of MEP amplitudes recorded in response to 5Hz rTMS between before and 
after drug withdrawal (t = -2,831, p = 0.015). Of note, the mean slope of MOH-a data 
was not significantly different from that for HVs (t = 0.854, p = 0.400). 
Mean days with headache per month and the mean number of tablets taken per 
month were also significantly decreased 1 month after withdrawal compared to 
baseline in patients with MOH (t = 12.338, p < 0.001; t = 5.252, p < 0.001 respectively) 
(Table 1). Moreover, there was significant negative correlation between the 
percentage reduction of days with headache at 1-month after withdrawal and the 
relative variation of the slope of the linear regression of MEP amplitudes recorded in 
response to 5 Hz rTMS (r = −0.637, p = 0.019) (Figure 3). 
 
Table 1. Demographics characteristics of study participants and headache profiles of patients. Data 
expressed as mean ± SD. HV healthy volunteers; MOH medication overuse headache patients before (MOH-
b) and after (MOH-a) acute medication withdrawal; N number of subjects. 
  HV (n = 16) MOH-b (n = 13) MOH-a (n = 13) 
 Women (n) 12 11 11 
 Age (years) 32.1 ± 10.2 34.5 ± 9.8  
 Duration of history of migraine (years)  13.5 ± 10.3  
 Days with headache/month (n)  24.4 ± 6.2 5.0 ± 4.8 * 
 Severity of headache attacks (0–10)  8.7 ± 1.8 7.3 ± 2.6 
 Nausea/vomiting (n)  12  
 Photophobia (n)  11  
 Phonophobia (n)  13  
 Pulsating (n)  12  
 Duration of the chronic headache (month)  41.9 ± 24.6  
 Tablet intake/month (n)  42.5 ± 43.3 0.7 ± 1.2 * 
*p < 0.001 vs. MOH before withdrawal 
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Table 2. Transcranial magnetic stimulation (TMS) resting motor thresholds (RMT) and motor evoked 
potential (MEP) 1st amplitude (Log transformed) and slope of the linear regression line from the 1st to the 
10th stimulus of the train in MOH subgroup (n = 13) before and after 3 weeks of drug withdrawal. Data 
expressed as mean ± SD. HV healthy volunteers; CM chronic migraine patients; MOH medication overuse 
headache patients; N number of subjects; § p < 0.05 v. HV. 
  HV (n = 16) MOH-b (n = 13) MOH-a (n = 13) 
 1 Hz repetitive TMS train    
 RMT (%) 54.9 ± 11.3 60.0 ± 11.4 61.2 ± 8.8 
 1st MEP amplitude 2.2 ± 0.3 2.3 ± 0.5 2.2 ± 0.5 
 MEP slope  - 0.0020 ± 0.0151 - 0.0056 ± 0.0286 - 0.0050 ± 0.0320 
 5 Hz repetitive TMS train    
 RMT (%) 54.6 ± 11.4 59.2 ± 9.0 58.5 ± 6.6 
 1st MEP amplitude 2.3 ± 0.3 2.4 ± 0.3 2.2 ± 0.5 
 MEP slope 0.0104 ± 0.0309 - 0.0303 ± 0.0255 § 0.0006 ± 0.0300 * 
*p < 0.05 vs. MOH before withdrawal 
 
 
 
Figure 1. Motor evoked potentials (MEP) elicited by repetitive transcranial magnetic stimulation trains delivered 
at 1 Hz [left panel] and 5 Hz [right panel] at 120% resting motor threshold in healthy volunteers (HV), in medication 
overuse headache (MOH) patients before (MOH-b) and after (MOH-a) 3-week drug withdrawal. 
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Figure 2. Bar charts representing the motor evoked potential (MEP) amplitude slope of the linear regression line 
from the 1st to the 10th stimulus of the 1 Hz [left panel] and 5 Hz [right panel] train of transcranial magnetic 
stimulations in healthy volunteers (HV) and medication overuse headache patients before (MOH-b) and after 
(MOH-a) 3-week drug withdrawal. 
 
 
 
Figure 3. Percentage changes in the mean monthly headache days and the slope of the linear regression after 
patients with medication overuse headache completed a 3-week medication withdrawal program. 
 
 
 
Discussion 
The main finding of the present study was that a standard withdrawal program for 
patients overusing medication restored normal short-term synaptic potentiation in 
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the primary motor cortex of patients with MOH. Several neurobiological factors can 
account for these results.  
In healthy subjects, trains of rTMS alter MEP amplitudes during and immediately 
after stimulation depending on the frequency and intensity of stimulation. When 
applied over the motor cortex at suprathreshold intensity (120% RTM), high 
frequency (5 Hz) rTMS increases MEP amplitudes [8], whereas low frequency 
stimulation (1 Hz) diminishes MEP amplitudes. Therefore, rTMS produces plastic 
changes in motor cortex excitability that outlast the period of stimulation for a period 
of minutes to hours [8–10].  
The results of this study confirm our previous finding of dysfunctional short-term 
synaptic potentiation in patients with MOH [6]; in this study, trains of high-frequency 
rTMS induced a paradoxical decrease in amplitude in patients with MOH prior to 
medication withdrawal. This neurophysiological dysfunction may reflect a general 
alteration in plasticity and learning processes in the MOH brain. Moreover, the 
absence of these abnormalities in another group of patients with chronic migraine 
patients without MOH suggests that these findings are specifically related to 
medication overuse. In our previous study, this conclusion was underscored by the 
observation that longer durations of medication overuse were associated with more 
pronounced dysfunction of short term potentiation in the motor cortex [6], as 
previously demonstrated for the somatosensory cortex [2]. 
The present results expand on our previous findings by demonstrating that 
complete medication withdrawal restores normal short-term potentiation 
mechanisms within the motor cortex of patients with MOH. Moreover, withdrawal-
related normalisation of rTMS responses corresponded to a change from a chronic 
migraine to episodic migraine as indicated by a relative reduction in the number of 
monthly headache days. 
Since the primary motor cortex is involved in several aspects of pain integration 
and modulation, likely influencing affective or sensory components of pain or by top-
down activation of descending antinociceptive systems [11, 12], drug withdrawal 
may induce the normalisation of a complex network involving brain areas that 
participate in pain modulation and control such as M1. Consistent with this idea, 
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previous studies have associated the discontinuation of medication overuse with the 
normalisation of several neurophysiological parameters and morphological features 
in brain areas of the salient network (also known as the “pain matrix”) [13]. 
Pain-related cortical potentials [4, 14] and spinal noxious flexion reflex responses 
[15] are sensitised in patients with MOH. These abnormal responses normalise after 
withdrawal treatment [4, 14, 15]. Perrotta and colleagues found that at the spinal 
level, the sensitisation process in MOH was related at least in part to insufficient 
descending inhibition from the brainstem, subserving the counterirritation 
phenomenon activated by heterotopic pain stimulation to suppress incoming 
nociceptive information [15]. The supraspinal antinociceptive structures include the 
periaqueductal grey, rostral ventromedial medulla, thalamus, nucleus raphe magnus, 
and nucleus reticularis gigantocellularis [16]. Altered structural integrity and 
functional connectivity of descending pain modulatory areas such as the 
periaqueductal grey [17–20] and thalamic nuclei [21] has been repeatedly identified 
in patients with MOH. These structures are all interconnected with areas belonging 
to the salient network such as the sensorimotor cortex and orbitofrontal and anterior 
cingulate cortices [13]. 
A voxel-based morphometry study identified significant increases in grey matter 
volume in the midbrain (including periaqueductal grey matter) of patients with MOH 
and subsequent decreases in volume after the discontinuation of medication 
overuse. Of note, low grey matter volume in the orbitofrontal cortex before 
withdrawal was associated with a poor response to drug discontinuation in a previous 
study [17]. In another study, the orbitofrontal cortex was less connected both 
metabolically [22] and functionally to nociceptive input regions such as spinal 
trigeminal nucleus and cerebellum [23] in patients with MOH before drug 
withdrawal, whereas these connections were normalized after drug withdrawal [22, 
23]. Taken together, these data support the hypothesis that medication overuse 
promotes maladaptive neurophysiological and morphological changes in the brain. 
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Conclusion 
In conclusion, we demonstrate that the dysfunction of short-term plasticity 
mechanisms in patients with MOH are alleviated by the discontinuation of 
medication overuse. On this premise, clinical improvements associated with 
withdrawal treatment may be related to the restoration of physiological brain 
plasticity. Our findings underscore the importance of initiating withdrawal treatment 
as early as possible in patients with MOH in order to facilitate normalisation of brain 
plasticity mechanisms. Future studies in a larger cohort of patients are necessary to 
determine the exact relationships between neurophysiological changes and clinical 
variables in patients with MOH, and whether the normalisation of such brain 
processes allow patients to regain clinical efficacy from acute and prophylactic 
migraine medications.  
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4. DISCUSSION AND FUTURE PERSPECTIVES 
 
Migraine pathophysiology represents a complicated puzzle, which has not been 
completely disentangled. 
Overall, the scientific evidences highlight the concept that both episodic and 
chronic migraine are characterized by neurophysiological dysfunctions in sensory 
processing and motor cortex plasticity, that probably represent permissive factors 
predisposing the brain to migraine attacks and pain chronification. The 
understanding of such dysfunctions can be useful not only to shed light on the 
complex mosaic of migraine pathophysiology, but also to set targets for 
neuromodulatory therapeutic strategies to prevent migraine attacks and interfere 
with the mechanisms involved in migraine chronification. 
Chronic migraine is characterized by a maladaptive plasticity. From an 
electrophysiological point of view, sensory cortices in chronic migraine show 
abnormalities that have also been reported in episodic migraineurs during attacks, as 
if chronic migraine was a “never ending migraine attack”. Indeed, sensory cortices in 
chronic migraine are sensitized and exhibit normal habituation. Contrarily, in 
medication overuse headache (MOH) patients, sensitization and deficient 
habituation were demonstrated in the sensory cortices (for a review see Coppola et 
al, 2013). 
Even though no differences were found in motor cortex excitability between 
chronic migraine, episodic migraine and healthy subjects, some studies revealed 
alteration in motor cortex plasticity. 
Indeed, a paradoxical inhibitory response was found after facilitatory high-
frequency repetitive transcranial magnetic stimulation of the motor cortex in chronic 
migraine (Cosentino et al, 2014) 
The interest in studying motor cortex plasticity in chronic pain syndrome, came 
from the results of several neurostimulation studies showing that both invasive and 
non-invasive neuromodulatory techniques applied on the motor cortex could achieve 
an analgesic effect in various kinds of chronic pain (Leufaucheur et al, 2001; Fregni et 
al, 2006), probably through the activation of a top-down control of the 
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thalamocortical pathways or favouring opioids release (see Dos Santos et al, 2016). 
Furthermore, chronic pain can induce a reorganization of the motor cortex, whose 
extension is positively associated to pain intensity (Lotze et al, 1999). 
Comparing motor cortex responses to trains of facilitating (high-frequency) and 
inhibiting (low-frequency) TMS in patients affected by MOH with those affected by 
chronic migraine (without medication overuse) and with healthy subjects, we showed 
that in MOH patients, rTMS-5 Hz depressed instead of potentiating MEP amplitudes 
with a significantly different response from that in HVs and CM patients (Cortese et 
al, 2018). 
This finding suggests that CM and MOH patients, although exhibiting a similar 
phenotypic expression, represent distinct pathological conditions, characterized by 
different pathophysiological mechanisms of migraine chronification. 
Furthermore, we found that the slope of the linear regression of MEP amplitudes 
was negatively correlated with the duration of overuse headache in MOH patients. 
That means that medication overuse itself may probably promote plastic 
modifications in the motor cortex. This hypothesis is also supported by the finding of 
different CSP duration in MOH patients according to the different overused drug.  
Studies about the relationship between chronic migraine and motor cortex 
plasticity could be interesting, not only to disclose the neurophysiological 
mechanisms underpinning learning processes and plastic behaviour in chronic 
migraine, but also to develop future therapeutic targets and interventions. 
Interestingly we found that a 3-week pharmacological wash-out program 
restored a normal short-term synaptic potentiation in the primary motor cortex of 
patients with medication overuse headache. This finding has important 
pathophysiological implications. Firstly, a direct effect of medication overuse on the 
brain, causing short-term plasticity dysfunctions, may be hypothesized. Secondly, 
since such dysfunctions are reversible after drug discontinuation, it’s conceivable that 
the restoration of physiological brain plasticity could be the neurophysiological 
underpinning of the clinical improvement. 
The presence of brain dysfunctions in MOH patients that can be reverted after 
detoxification was also described using metabolic and functional neuroimaging 
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techniques. These findings support the importance of early medication withdrawal in 
MOH patients also to prevent the development of more pronounced alterations in 
brain plasticity. 
Probably drug withdrawal is able to induce the normalization of a complex 
network involving areas participating in pain modulation, including the primary 
motor cortex. Indeed, this area is known to be involved in several aspects of pain 
integration and modulation, likely influencing affective or sensory components of 
pain or by top-down activation of descending antinociceptive systems. 
Our findings have important implications in neurorehabilitation. 
Since neurorehabilitation includes all the approaches aimed to aid recovery from 
a nervous system injury or dysfunction and reduce disability, drug withdrawal in 
medication overuse headache could be completely considered a neurorehabilitation 
strategy. Indeed, its objective is brain recovery both from an electrophysiological 
point of view, with the restoration of physiological cortical plasticity, and from a 
clinical point of view, reducing the disability caused by chronic migraine and inducing 
the conversion from chronic to episodic migraine. 
Even though, sometimes, simple information and advice may be enough to 
achieve headache improvement, for several patients drug discontinuation could be 
quite hard. Patients need to be guided by the physician during the process since 
withdrawal symptoms (headache, nausea, vomiting, arterial hypotension, 
tachycardia, sleep disturbances), lasting generally for 2–10 days, could complicate 
the discontinuation phase and induce patients to fall back into medication overuse. 
The normalization of brain plasticity after medication discontinuation 
underscores the importance of initiating withdrawal treatment as early as possible in 
patients with medication overuse headache in order to induce the restoration of 
physiological brain plasticity and prevent the development of more pronounced 
alterations in brain plasticity and learning processes. 
An interesting future perspective could be to use neuromodulatory strategies in 
order to normalize brain plasticity in medication overuse headache patients, thus 
helping them in the withdrawal treatment.  
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Remarkably, the response to high frequency stimulation could be used as a 
biomarker during the discontinuation process and to distinguish between chronic 
migraine patients with or without medication overuse. 
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6. APPENDIX: OTHER SCIENTIFIC WORKS ON MIGRAINE 
 
This appendix collects three research articles on episodic and chronic migraine that I 
have published during my PhD program, in collaboration with my research team. 
Patients were recruited from our headache clinic and underwent 
neurophysiological examinations in our laboratories. The results of these studies 
represent an important tile in the complex puzzle of migraine pathophysiology, and 
particularly in the understanding of cortical excitability and plastic mechanisms in 
both somatosensory and motor cortex. 
The last work, regarding “Short-term cortical synaptic depression/potentiation 
mechanisms in chronic migraine patients with or without medication overuse”, 
showed a maladaptive plasticity of the motor cortex in chronic migraine with 
medication overuse, giving us the hint to deepen our understanding about this field, 
conceiving a study about the effect of detoxication on short-term synaptic plasticity  
of the motor cortex in MOH patients, which has been chosen as the topic of my PhD 
final work.  
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A. Anodal transcranial direct current stimulation over the left temporal pole 
restores normal visual evoked potential habituation in interictal migraineurs 
FRANCESCA CORTESE1§, FRANCESCO PIERELLI1,2, ILARIA BOVE1, CHERUBINO DI LORENZO3, MAURIZIO 
EVANGELISTA4, ARMANDO PERROTTA2, MARIANO SERRAO1, VINCENZO PARISI5, GIANLUCA COPPOLA5 
 
1 Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy 
2 INM Neuromed IRCCS, Pozzilli (IS), Italy  
3 Don Carlo Gnocchi, Onlus Foundation, Milan, Italy 
4 Università Cattolica del Sacro Cuore/CIC, Istituto di Anestesiologia, Rianimazione e Terapia del Dolore, Rome, Italy 
5 G. B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neuro-Ophthalmology, Rome, Italy 
 
Background 
Migraine is a neurological disorder that is characterized by recurrent clinical attacks 
separated by variable-length headache-free intervals. Although the pathogenesis of 
migraine is far from completely understood, clinical neurophysiology and 
neuroimaging studies in recent decades have disclosed subtle functional and 
morphological abnormalities that manifest during the interictal phase and distinguish 
migraineurs from normal healthy subjects [1–3]. Among the various subcortical and 
cortical areas implicated in migraine pathophysiology, emerging evidence highlights 
the temporal pole (TP) as a key neural substrate. In humans, the TP serves as a 
multimodal neural hub that receives and integrates various sensory modalities 
including olfactory, auditory, taste, and visual inputs. Moreover, the TP participates 
in the ventral visual stream (VVS) for visual information processing [4–6]. During an 
olfactory task, interictal migraineurs exhibited significantly higher brain glucose 
metabolism in the left TP compared to control subjects [7]. Moreover, BOLD signal in 
the TP in response to noxious stimulation was reduced in interictal patients compared 
to patients who were actively experiencing a migraine [8, 9]. In resting-state MRI 
studies comparing interictal migraineurs to healthy control subjects, decreased grey 
matter density was observed in the left TP [10] and the left TP exhibited decreased 
connectivity with components of the default-mode network [11]. Finally, the TP was 
implicated as an important area for differentiating patients with migraine from 
healthy control subjects in a cross-sectional brain MRI investigation [12]. Taken 
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together, these findings suggest that the TP is both intricately related to the 
pathophysiology of migraine and sensitive to the cyclical recurrence of migraine 
attacks.  
Transcranial direct current stimulation (tDCS) is a non-invasive technique for 
neuromodulation in humans that affects cortical excitability in a polarity-specific 
manner [13, 14]. Anodal polarization increases the excitability of cortical areas below 
electrodes, whereas cathodal polarization typically decreases cortical excitability 
[15]. A number of tDCS studies in different pain disorders [16, 17] have demonstrated 
that tDCS is well-tolerated by patients [18]. Anodal tDCS proved effective over either 
the motor cortex or the dorsolateral prefrontal cortex when used as prophylactic 
strategy both in episodic [19] and chronic [20, 21] migraine. Moreover, some studies 
reported that, in addition to the therapeutic effects, tDCS over the visual cortex also 
normalized interictal cortical hyperresponsivity in episodic migraine [22].  
Nonetheless, to our knowledge, no study to date has targeted the TP for anodal tDCS 
in migraine, to enhance interictal temporal lobe activity and thereby interfere with 
an aspect of migraine pathophysiology. Thus, we examined whether anodal 
stimulation of the TP could restore normal function of the TP and thus physiological 
information processing in migraine. Moreover, given that the TP processes all kinds 
of sensorial information except for somatosensory information, we examined the 
habituation responses of evoked potentials to somatosensory stimuli (as a negative 
control) as well as visual stimuli.  
 
Methods 
Participants 
Forty patients with migraine without aura (diagnosed in accordance with the 
International Classification of Headache Disorders III beta edition) were recruited 
from our headache clinic (Table 1). Of these, 4 patients were excluded because they 
did not meet the primary inclusion criteria (see below). Subjects were included if they 
were between 18 and 65 years of age and had at least a 1-year clinical history of 
migraine with 2–8 attacks per month. The use of preventive anti-migraine medication 
was not permitted during the 3 months preceding the study. The primary inclusion 
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criterion was being attack-free for at least 3 days before and after each recording 
sessions, and was verified by headache diary and telephone or e-mail interview. 
Subjects were excluded from the study if they were regularly taking medication (e.g., 
antibiotics, corticosteroids, antidepressants, benzodiazepines, or prophylactic 
migraine medication) except for contraceptive pills; if they did not have a best-
corrected visual acuity of > 8/10; and if they had a history of other neurological 
disease, systemic hypertension, diabetes or other metabolic disease, autoimmune 
disease, or any other type of primary or secondary headache. Female participants 
were always recorded mid-menstrual cycle. All participants received a complete 
description of the study and provided written informed consent. The study was 
approved by a local ethical review board and was conducted in accordance with the 
Helsinki Declaration. 
Table 1 Descriptive statistics of clinical and demographic characteristics of migraine patients between attacks in 
the sham and real group 
 Real (n = 18) Sham (n = 18) p value 
Women (n) 13 11 0.495 
Age (years) 28.6 ± 7.6 26.9 ± 4.9 0.430 
Duration of migraine history (years) 15.6 ± 8.3 12.4 ± 7.0 0.220 
Attack frequency/month (n) 5.0 ± 3.2 3.9 ± 2.1 0.231 
Attack duration (hours) 17.1 ± 17.4 18.1 ± 14.8 0.854 
Visual analogue scale (n) 7.0 ± 0.7 6.6 ± 1.2 0.230 
Days from the last migraine attack (n) 8.5 ± 8.5 11.7 ± 13.0 0.388 
Family history of migraine (%) 51.4 48.6 0.210 
Acute medication intake/month (n) 2.0 ± 1.9 2.0 ± 1.8 0.996 
Data are expressed as means ± SD    
 
Experimental procedure 
The 36 enrolled patients were equally randomized to receive anodal tDCS (N = 18) or 
sham tDCS (N = 18). Randomization was conducted using a secure web-based 
database. For all patients, visual evoked potential (VEP) and somatosensory evoked 
potential (SSEP) recordings were performed in a random order during a single session 
before and immediately after real or sham tDCS. All recordings were performed in 
the afternoon (between 14:00 and 18:00) by the same investigators (F.C. and I.B.); 
these investigators were not involved in recruitment, inclusion, or randomization of 
subjects, and had no interactions with participants prior to the examination. All 
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recordings were numbered anonymously and analysed offline in a blinded fashion by 
a single investigator (G.C.), who was not blinded to the order of the blocks. 
 
tDCS 
tDCS (2 mA, 20min) was delivered using a constant current electrical stimulator 
(Brainstim®, EMSmedical) through a pair of surface electrodes: the anode was placed 
over the left temporal pole and the cathode was placed above the right shoulder. The 
electrodes were square in shape (25 cm2), 6-mm thick, and covered in a saline-soaked 
sponge. Current was delivered at a density of 0.08 mA/cm2, resulting in a total charge 
of 96 mC/cm2. These parameters are below the threshold for possible tissue damage 
[14]. During stimulation, tDCS is not usually perceived except for occasional short-
lasting itching sensations below the electrodes.  
The stimulation site over the left temporal pole was determined by moving 
laterally 40% of the intra-auricular distance from the vertex and anteriorly 5% of the 
distance from inion to nasion [23, 24]. The target site was located approximately 
halfway between the T7 and FT7 EEG positions of the international 10–20 system. 
This positioning method, although less accurate than neuronavigation-based 
techniques, adequately correlates with MRI-guided stereotactic approaches [25, 26]. 
For sham tDCS, the electrode positions and stimulation intensity were the same 
as that used for anodal stimulation, but current was only applied for the first and last 
30 seconds of the 20-min period. This was done so that patients would not easily be 
able to distinguish between real tDCS and sham tDCS sessions. Participants in the 
sham and real arms guessed the type of stimulation in 5 and 6 cases out of 18 
respectively (chi2 = 0.717, p = 1.0). The experimenters who applied tDCS (F.C. and I.B.) 
were also blind to the nature of the procedure (real versus sham tDCS); rather, a third 
experimenter (C.D.L.) pre-programmed the stimulator and ensured the 
randomization order. 
 
VEP study 
Subjects were seated in a semi-dark, acoustically isolated room in front of a TV 
monitor surrounded by a uniform luminance field of 5 cd/m2. VEPs were elicited by 
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monocular stimulation of the right eye. Visual stimuli were full-field checkerboard 
patterns (contrast, 80%; mean luminance, 50 cd/m2) generated on the TV monitor 
and reversed in contrast at a reversal rate of 3.1 reversals per second. The viewing 
distance was 114 cm and single check edges subtended a visual angle of 15 min. 
Subjects were instructed to fixate with their right eye on a red dot in the middle of 
the screen while the contralateral eye was covered with a patch. VEPs were recorded 
from the scalp through silver cup electrodes positioned at Oz (active electrode) and 
at Fz (reference electrode as per the international 10–20 system). A ground electrode 
was placed on the right forearm. Signals were amplified by DigitimerTM D360 pre-
amplifiers (band-pass, 0.05–2,000 Hz; gain, 1,000) and recorded on a CEDTM power 
1401 device (Cambridge Electronic Design Ltd, Cambridge, UK). A total of 600 
consecutive sweeps (sweep duration, 200 ms) were collected and sampled at 4,000 
Hz. After offline application of a 100-Hz low-pass digital filter, cortical responses were 
partitioned into 6 sequential blocks of 100 (including at least 95 artefact-free 
sweeps). Responses in each block were averaged offline (block averages) using the 
SignalTM software package version 3.10 (CED Ltd). VEP latencies (N1, P1, and N2) and 
amplitudes (N1-P1 and P1-N2) were identified. Habituation was defined as the slope 
of the linear regression line for the 6 blocks.  
 
SSEP study 
SSEPs were elicited by electrical stimulation of the right median nerve at the wrist 
using a constant current square wave pulse (width, 0.1 ms; cathode proximal) with a 
stimulus intensity of 1.5-times the motor threshold and a repetition rate of 4.4 Hz. 
The active electrodes were placed over the contralateral parietal area (C3', 2 cm 
posterior to C3 as per the international 10–20 system; referenced to Fz), over the 
fifth cervical spinous process (Cv5; referenced to Fz), and over Erb’s point ipsilateral 
to the stimulus (referenced to the contralateral side). The ground electrode was 
placed on the right arm. SEP signals were amplified and recorded with the same 
hardware/software equipment described above for VEP recording. 
Subjects were seated in a comfortable chair in a well-lit room with their eyes 
open. Subjects were asked to fix their attention on the stimulus-induced thumb 
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movement. During continuous median-nerve stimulation at the wrist, 500 sweeps 
(sweep duration, 50 ms) were collected and sampled at 5000 Hz. A total of 500 
artefact-free evoked responses were recorded and averaged for each subject (grand 
average). After digital filtering of the signal between 0–450 Hz, various SEP 
components (N9, N13, N20, P25, and N33) and their respective peak-to-peak 
amplitudes (N9-p, N13-p, N20-P25, and P25-N33) were identified. Thereafter, based 
on the observation of a habituation effect from the 2nd block of 100 averaged 
responses onwards in previous studies [27, 28], the first 200 evoked responses were 
partitioned into 2 sequential blocks of 100 (including at least 95 artefact-free 
sweeps). Each block was averaged offline (block averages) and analysed for N20–P25 
amplitudes. Habituation was expressed as the slope of the linear regression line for 
the 2 blocks [28]. 
For both VEPs and SSEPs, artefacts were automatically rejected using the SignalTM 
artefact rejection tool if the signal amplitude exceeded 90% of the analogue-to-digital 
converter (ADC) range. Signal was corrected offline for DC drift. 
 
Statistical analysis 
Data were collected and analysed in a blinded fashion by a single investigator (V.P.) 
using Statistica for Windows (StatSoft Inc., Tulsa, USA) version 8.0 software. Sample 
size calculations were based on a ketogenic diet clinical trial that examined the same 
evoked potentials [29] with a desired power of 0.80 and an α error of 0.05. Since our 
primary endpoint was to discover differences between the effects of real and sham 
tDCS on habituation, we used the amplitude habituations of the N1–P1 VEP and N20–
P25 SSEP cortical components in the 2 conditions (before versus after ketogenic diet) 
to compute the sample size. The minimal required sample size was calculated to be 
16 subjects for VEP habituation and 9 subjects for SSEP habituation. 
A Kolmogorov-Smirnov test showed that VEP and SSEP component latencies and 
amplitudes had a normal distribution. General linear models approach was used to 
analyse the ‘between-factor’ × ‘within-factors’ interaction effect. The between-
subject factor was ‘group’ (real tDCS versus sham tDCS) or ‘time’ (before stimulation 
versus after stimulation) and the within-subject factor was ‘block’. Three models of 
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repeated measures analysis of variance (ANOVA), two for VEPs (N1-P1 and P1-N2) 
and another for SSEPs, followed by univariate ANOVA, were used to investigate the 
interaction effect. Moreover, in order to analyse the slope of the linear regression (as 
a measure of habituation), we used a rm-ANOVA with the between-subject factor 
‘group’ (real tDCS versus sham tDCS) and the within-subject factor ‘time’ (before 
stimulation versus after stimulation). Univariate results were analysed only if Wilk’s 
Lambda multivariate significance criterion was achieved. The sphericity of the 
covariance matrix was verified with the Mauchly Sphericity Test; in the case of 
violation of the sphericity assumption, the Greenhouse-Geisser epsilon adjustment 
was used.  
In the rm-ANOVA and ANOVA models, partial eta2 (η_p2) and observed power 
(op) were used as measures of effect size and power, respectively. To identify the 
comparison(s) contributing to major effects, we performed post hoc Tukey Honest 
Significant Difference (HSD) tests. 
One-way ANOVA tests were used to compare the baseline grand averaged VEP 
and SSEP latencies and amplitudes between sham and real tDCS. Paired-sample t 
tests were used to compare the grand averaged VEP and SSEP latencies and 
amplitudes before vs. after both sham and real tDCS. P values less than 0.05 were 
considered statistically significant. 
 
Results 
Basic neurophysiological parameters 
VEP and SSEP recordings were obtained from all participants. The grand averaged 
VEP latencies (N1, P1, and N2; Table 2) and SEP latencies (N9, N13, N20, P25, and 
N33; Table 3) as well as their corresponding amplitudes (VEP: N1–P1 and P1–N2; SEP: 
N9, N13, N20–P25, and P25–N33) were not significantly different between real and 
sham tDCS groups (P > 0.05). Before stimulation, both groups showed positive slope 
values indicating a lack of habituation in response to visual (N1–P1: real tDCS = 
+0.112, sham tDCS = +0.059; P1–N2: real tDCS = +0.055, sham tDCS = +0.039) and 
somatosensory (real tDCS = +0.448, sham tDCS = +0.234) repetitive stimulations. 
 
  52 
Effects of tDCS on neurophysiological parameters 
The grand averaged VEP latencies (N1, P1, and N2; Table 2) and SSEP latencies (N9, 
N13, N20, P25, and N33; Table 3) as well as their corresponding amplitudes (VEP: N1–
P1 and P1–N2; SSEP: N9, N13, N20–P25, and P25–N33) were not significantly 
different before and after stimulation in both the real and sham tDCS groups (P > 
0.05).  
 
Table 2 Latencies (in milliseconds) and amplitudes (μV) of VEPs in migraine patients’ groups undergoing real or 
sham transcranial direct current stimulation (tDCS) before and after intervention 
Electrophysiological parameters Real (n = 18) 
Before 
 
After 
Sham (n = 18) 
Before 
 
After 
N1 80.3 ± 5.7 78.9 ± 6.4 78.4 ± 2.0 78.5 ± 3.1 
P1 105.5 ± 6.1 105.2 ± 5.8 105.1 ± 4.3 106.7 ± 4.7 
N2 146.1 ± 8.9 146.9 ± 9.7 150.7 ± 6.7 151.1 ± 6.8 
N1-P1 1st amplitude block (μV) 8.3 ± 3.1 8.9 ± 3.6 7.2 ± 2.7 6.7 ± 2.4 
N1-P1 amplitude slope 0.112 ± 0.315 - 0.236 ± 0.339 ** 0.059 ± 0.241 0.038 ± 0.182 
P1-N2 1st amplitude block (μV) 8.3 ± 3.1 8.9 ± 4.2 6.4 ± 3.4 6.3 ± 2.9 
P1-N2 amplitude slope 0.055 ± 0.507 - 0.345 ± 0.569 0.039 ± 0.272 - 0.001 ± 0.269 
Data are expressed as means ± SD. ** = p < 0.01 before vs. after the intervention 
 
 
Table 3 Grand-average somatosensory evoked potentials (SSEPs) latencies and amplitudes in migraine patients’ 
groups undergoing real or sham transcranial direct current stimulation (tDCS) before and after intervention 
Electrophysiological parameters Real (n = 18) 
Before 
 
After 
Sham (n = 18) 
Before 
 
After 
N9 (ms) 9.5 ± 0.6 9.7 ± 0.8 9.5 ± 0.6 9.6 ± 0.6 
N13 (ms) 13.2 ± 0.8 13.3 ± 0.8 13.1 ± 0.7 13.2 ± 0.7 
N20 (ms) 18.8 ± 0.9 19.0 ± 0.8 18.6 ± 1.1 18.8 ± 1.1 
P25 (ms) 23.6 ± 2.2 23.9 ± 2.1 22.9 ± 2.2 23.2 ± 2.2 
N33 (ms) 31.5 ± 2.6 31.5 ± 1.6 31.9 ± 2.1 31.5 ± 1.3 
N9-p (μV) 4.1 ± 1.6 3.8 ± 1.4 3.5 ± 1.4 3.5 ± 1.9 
N13-p (μV) 2.0 ± 0.8 2.0 ± 0.6 2.0 ± 0.6 1.8 ± 0.7 
N20-P25 (μV) 2.3 ± 1.3 2.4 ± 1.5 2.3 ± 0.7 2.1 ± 0.9 
P25-N33 (μV) 1.3 ± 0.5 1.3 ± 0.9 1.2 ± 0.5 1.0 ± 0.5 
N20-P25 1st amplitude (μV) 2.4 ± 1.1 2.2 ± 1.2 2.3 ± 0.7 2.2 ± 0.6 
N20-P25 amplitude slope 0.448 ± 0.710 0.315 ± 0.543 0.234 ± 0.406 0.213 ± 0.481 
Data are expressed as means ± SD     
 
 
 
In the rm-ANOVA model using the VEP N1–P1 peak-to-peak block amplitude as 
the dependent variable, the multivariate test was significant for the ‘group’ × ‘time’ 
× ‘block’ interaction effect (F5,340 = 3.290, p = 0.006). The univariate rm-ANOVA for 
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N1–P1 peak-to-peak amplitudes confirmed a significant interaction factor effect 
(Greenhouse-Geisser epsilon adjustment applied, F4.1,282.1 = 3.29, ε = 0.83, p = 0.01, 
partial η2 = 0.05, op = 0.89) in the multivariate test. At the post-hoc analysis 1st N1-
P1 VEP amplitude block did not differ between before and after both stimulations. 
The linear regression N1–P1 slope of VEP amplitudes over all blocks was significantly 
different between before and after stimulation (F1,34 = 5.21, p = 0.029, partial η2 = 
0.133, op = 0.60; raw data are shown in Figure 1).  
 
 
 
 
Fig. 1 Left panel: Amplitudes (mean ± standard error of the mean) of the N1–P1 visual evoked potential (VEP) component in 6 
sequential blocks of 100 recordings are shown before and after sham tDCS (upper panel) and anodal tDCS (lower panel). Right 
panel: The bar graph represents the habituation slope of VEP N1–P1 peak-to-peak amplitudes (mean ± standard error of the 
mean) before and after sham tDCS and real tDCS. The arrow highlights interictal VEP habituation that was reduced before real 
tDCS but normalized after. ** = p < 0.01 before vs. after the intervention 
 
 
 
A post-hoc analysis showed that the slope of VEP amplitudes from block 1 to block 
6 was positive before the intervention in both the real tDCS (+0.112) and sham tDCS 
(+0.059) groups, whereas after the intervention these values were negative in the 
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real tDCS group (−0.236, p = 0.003 versus before stimulation) but positive in the sham 
tDCS group (+0.038, p > 0.05 versus before stimulation) (Figure 1, right panel). 
In the rm-ANOVA model using the VEP P1–N2 peak-to-peak block amplitude as the 
dependent variable, the ‘group’ × ‘time’ × ‘block’ interaction effect was not significant 
(F5,340 = 1.55, p = 0.171) in the multivariate test (Figure 2). 
 
 
 
Fig. 2 Left panel: Amplitudes (mean ± standard error of the mean) of the P1–N2 visual evoked potential (VEP) component in 6 
sequential blocks of 100 recordings are shown before and after sham tDCS (upper panel) and real tDCS (lower panel). Right 
panel: The bar graph represents the habituation slope of VEP P1–N2 peak-to-peak amplitudes (mean ± standard error of the 
mean) before and after sham tDCS and real tDCS. 
 
 
 
In the rm-ANOVA model using the SSEP N20–P25 peak-to-peak block amplitude as 
the dependent variable, the ‘group’ × ‘time’ × ‘block’ interaction effect was not 
significant (F1,68 = 0.19, p = 0.659) in the multivariate test (Figure 3).  
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Fig. 3 Left panel: Amplitudes (mean ± standard error of the mean) of the N20–P25 somatosensory evoked potential (SSEP) 
component in 2 sequential blocks of 100 recordings are shown before and after sham tDCS (upper panel) and real tDCS (lower 
panel). Right panel: The bar graph represents the habituation slope of SSEP N20–P25 peak-to-peak amplitudes (mean ± standard 
error of the mean) before and after sham tDCS and real tDCS. 
 
 
 
Discussion 
The present study mainly revealed that a single session of anodal tDCS over the left 
temporal pole restored normal visual but not somatosensory habituation in interictal 
migraineurs. 
Neurophysiological studies have shown that interictal migraineurs exhibit 
dysfunctional sensory information processing in the form of habituation deficits in 
response to various sensory inputs, including visual and somatosensory inputs [2]. 
Recent neuroimaging studies have revealed subtle microstructural alterations in the 
brains of patients with migraine in areas associated with the ictal-interictal cycle. 
Among these studies, some evidence highlights a pathophysiological role for the TP 
in migraine [7–12].   
The TP region encompasses the most anterior segment of the temporal lobe and 
receives extensive inputs from visual regions of the thalamus [30, 31]. Additionally, 
the TP is highly interconnected with the amygdala, hippocampus, superior temporal 
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gyrus, hypothalamus, occipitobasal cortex, prefrontal regions, and insula, suggesting 
its participation in autonomic regulation, memory, and emotional processing [32, 33]. 
The TP is considered a multisensory associative cortex because it is also connected to 
the main sensory systems of the temporal lobe, including the visual, auditory, 
olfactory, and gustative systems, but not the somatosensory system [32, 34]. Indeed, 
neuroimaging studies have demonstrated subregional activation of the TP in 
response to specific sensory stimuli, with the ventromedial aspect of the TP having a 
predominant role in higher order visual information processing [34] as part of the 
VVS.  
Our finding that anodal (excitatory) stimulation of the left TP restored 
physiological visual information processing but not somatosensory processing in 
interictal migraineurs is largely consistent with the abovementioned roles of the left 
TP in high-level multimodal perceptual processing. A selective effect of tDCS over the 
TP on visual information processing is probably related to the role of the TP in the 
VVS and its lack of participation in somatosensory elaboration. Interestingly, another 
study observed similar normalization of abnormal interictal VEP habituation in 
response to the application of tDCS over the occipital cortex in migraineurs [22]. This 
can be explained either by a direct interconnection between the TP and occipital 
cortex along the VVS or an indirect effect of the tDCS on brain structures that 
positively modulate both cortices.  
The VVS is involved in visual recognition and in the assignment or retrieval of a 
given meaning for visual information [35]. After early activation of the occipital area, 
the complexity of representation of visual information increases as information flows 
to the anterior regions of the VVS, with the TP located at the end of the stream and 
sending backward facilitatory projections to the occipital cortex to optimize sensory 
processing (e.g., improve perception and learning) [35, 36]. Consistent with this 
evidence, we observed that the enhancement of TP activity with anodal tDCS 
improved VEP amplitude habituation, a basic form of learning [37], without affecting 
initial baseline excitability (reflected by non-significant changes in 1st block VEP 
amplitudes). In habituation paradigms, early and late responses can behave 
differently as a result of regulation by different mechanisms; according to the dual-
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process theory, increasing responsiveness (sensitization) competes with decreasing 
responsiveness (habituation) to determine final behavioural outcomes. Facilitation 
occurs at the beginning of the stimulus session and accounts for an initial temporary 
increase in response amplitude, whereas habituation occurs throughout the 
recording session and accounts for delayed decreases in responsiveness [38]. 
Therefore, our results regarding the selective effect of anodal tDCS on delayed 
habituation in migraineurs appear to be in line with the putative mechanism of tDCS; 
that is, the ability of tDCS to affect the potentiation of long-term learning processes 
and synaptic plasticity underlying learning and memory [39]. Alternatively, it has 
been shown that anodal tDCS exerts modulatory effects on thalamo-cortical circuits 
by increasing functional coupling between the thalamus and cortex [17, 40]. These 
experimental observations are of particular interest in migraine because 
independent research groups have previously reported reduced functional [41, 42] 
and morphological [43, 44] thalamic integrity coupled with decreased intracortical 
inhibition during visual stimulation in migraineurs [45, 46]. We thus can hypothesize 
that an alternative mechanism of action for anodal tDCS in the present study is 
increased thalamo-cortical activity, which in turn increased delayed inhibitory 
mechanisms to restore normal VEP habituation. 
Irrespective of the mechanism, the observation that tDCS over the left TP is able 
to restore normal VEP habituation in interictal migraineurs leads to hypothesize that 
together with the visual, motor, and dorsolateral prefrontal cortices [19, 20], the TP 
could represent a novel target for tDCS as a prophylactic strategy for treating 
migraine [47]. 
This study had some limitations. For example, we only stimulated the left TP, such 
that we cannot know whether anodal tDCS of the right TP would have yielded similar 
results. Several studies have shown divergent functional roles of the left and right TP, 
where the right TP is more involved in elaborating socio-emotional implications of 
multisensory perceptual stimuli [48] while the left TP is mostly implicated in 
perceptual decoding, semantic processing, and conceptualization [34]. Nonetheless, 
both the left and right TPs are joined via the anterior white commissure to advance 
multimodal perceptual analysis [32], such that the relevance of the right TP cannot 
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be discounted. Furthermore, the positioning method we used is accurate, although 
not as accurate as neuronavigation-based techniques, which are unfortunately only 
available for neurosurgical procedures in our clinic. Another shortcoming of the 
present study is the lack of inclusion of a healthy control group undergoing the same 
stimulations, although this would not add anything to the results of the study because 
the healthy subjects usually already habituate normally at the baseline, i.e. we cannot 
normalize the already normal information processing. 
 
Conclusions 
In conclusion, anodal but not sham tDCS selectively enhanced visual but not 
somatosensory habituation in interictal migraineurs probably by restoring normal 
inhibitory activity of the left TP. We propose that this effect can be explained by 
either a direct interference with short- and long-term synaptic plasticity mechanisms 
or an indirect potentiation of the thalamo-cortical circuit. Further studies are needed 
to determine whether TP stimulation also normalizes the habituation response to 
other sensory inputs, such as auditory and nociceptive inputs. Regardless of the 
underlying cellular and molecular mechanisms of our observed effect, we propose 
that the TP should be considered as a key site of involvement in the pathophysiology 
of migraine and as a potential therapeutic target. Clinical studies are needed to clarify 
whether repeated sessions of anodal tDCS improve TP function and connectivity in 
patients with migraine to ultimately reduce the number and severity of migraine 
attacks.  
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Background 
Although the pathophysiology of migraine remains unclear, neurophysiological 
studies performed over the last few decades have shown that patients affected by 
migraine exhibit interictal abnormalities in their cortical information processing 
system [1, 2]. These functional brain abnormalities are not constant; rather, they 
cyclically change until an attack occurs, whereupon the cortical responsiveness 
normalises [3]. The latter was demonstrated when information processing was 
assessed by cortical evoked potentials (EPs). In fact, the migraineur brain is frequently 
characterised by abnormal EP amplitude habituation in response to any kind of 
sensory stimulation [3]. We recently found that in migraineurs, the degree of EP 
abnormalities fluctuates over time, particularly in relation to the occurrence of 
migraine attacks (i.e. the degree of abnormalities is higher at long time intervals after 
an attack while it is minimal and within the normal range during an attack) [4–6]. 
Cortical excitability can also be examined noninvasively by applying transcranial 
magnetic stimulation (TMS) pulses over different areas of the cortex and then 
recording the evoked peripheral activity. TMS studies of the motor cortex rely on an 
objective measure, namely the motor-evoked potentials (MEPs) recorded from the 
peripheral muscles. In clinical practice and in scientific studies, corticospinal 
excitability is estimated objectively by examining the cortical motor threshold (or 
resting motor threshold, RMT), which is the minimal intensity of motor cortex 
stimulation required to elicit a MEP of minimal amplitude in the relaxed target 
muscle. The MEP size or amplitude can then be measured by setting the TMS intensity 
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to 115–125% of the individual’s RMT [7]. Lower MEP thresholds and larger MEP 
amplitudes suggest higher cortical excitability. In patients with migraine, 
controversial findings have been reported regarding the degree of motor cortex 
excitability. Globally, thresholds for MEPs were found to be normal [8–13], increased 
[14–16], or reduced [17–19] in migraineurs. 
However, whether these inconsistent findings result from variation in the cortical 
excitability related to the time interval between the ictal and interictal state remains 
unknown. 
Here, we sought to understand whether the actual MEP threshold and amplitude 
in patients with migraine varies on the basis of the time elapsed since the last attack 
and in comparison to healthy volunteers (HVs). Consistent with the abovementioned 
changes in EP according to the time elapsed from the last attack [4, 6], we 
hypothesised that motor cortex excitability would also become increasingly 
abnormal in patients with migraine as the time from the last migraine attack 
increased. 
 
Methods 
Participants 
Thirty-one patients affected by migraine without aura (MO) who consecutively 
attended the Headache Clinic of the ‘Sapienza’ University of Rome Polo Pontino, Italy, 
were enrolled in this study. Only the data from patients who had an interval of at 
least 3 days between the recording and their last or next migraine attack (checked by 
email or telephone) were included. We also excluded those participants who were 
taking any type of medication on a regular basis, except contraceptive pills. 
We evaluated the following clinical characteristics of the patients: duration of 
migraine disease (years), attack frequency (number/month), attack duration (hours), 
severity of headache attacks (0–10), and number of days elapsed since the last 
migraine attack (Table 1). This information was collected from participants’ 1-month 
headache diaries, which were obtained either during the screening visit or on the day 
of the recording session. 
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Table 1 Clinical and demographic characteristics of HVs and MO patients. Data are expressed as means ± 
SD 
  HV (n = 24) MO (n = 26) 
 Women (n) 16 18 
 Age (years) 30.4 ± 10.2 29.4 ± 6.8 
 Duration of migraine history (years)  13.9 ± 6.9 
 Attack frequency/month (n)  3.1 ± 2.7 
 Attack duration (hours)  22.3 ± 18.8 
 Visual analogue scale (n)  7.4 ± 1.5 
 Days from last migraine attack (n)  10.6 ± 8.4 
 
 
Twenty-four HVs with a similar age and sex distribution as the patients with MO 
(mean age ± standard deviation: 30.4 ± 10.2 years, 16 women) and without a personal 
or familial history of migraine or any detectable medical condition were used for 
comparison. All participants were right-handed. 
The physicians and neurophysiologists involved in the study were blinded to the 
electrophysiology and clinical history of the participants, respectively. This study was 
conducted in accordance with the Declaration of Helsinki and the study was approved 
by the Ethical Committee of the ‘Sapienza’ University of Rome Polo Pontino. All 
individuals provided written informed consent to participate in the study. 
 
Transcranial magnetic stimulation procedures 
TMS was delivered through a high-frequency biphasic magnetic stimulator 
(MagstimRapid, The Magstim Company Ltd., Whitland, South West Wales, UK), which 
wasconnected to a figure-of-eight coil with a maximal output of 1.2 Tesla. Firstly, we 
determined the optimal orientation and position of the coil (i.e. ‘hot spot’) over the 
left motor area for stimulating the first dorsal interosseous muscle. After that, we 
identified the RMT by using single TMS pulses; complete relaxation of the first dorsal 
interosseous muscle was checked by verifying the absence of electromyographic 
signals, both visually (on a monitor) and by acoustic feedback. The RMT was defined 
as the minimal intensity required to elicit an electromyographic response of at least 
50 μV with 50% probability in a fully relaxed muscle [7, 20–23]. 
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During TMS, patients were seated in a comfortable armchair and asked to remain 
fully relaxed with their eyes closed to ensure similar attention levels. We delivered 
10 single pulses of TMS (stimulus intensity: 120% of the RMT, rate: 0.1 Hz) and 
averaged the resulting MEPs. 
 
Statistical analysis 
All analyses were conducted with the Statistical Package for the Social Sciences (SPSS) 
for Windows, version 21.0. The normality of the data for each group of participants 
was tested with the Shapiro–Wilk test. Since the MEP amplitude showed a non-
Gaussian distribution, it was analysed with the non-parametric Mann-Whitney U-
test. As the RMT was normally distributed, it was analysed using independent-
samples t-tests. Spearman’s rho correlation test was used to search for correlations 
between the neurophysiological parameters and clinical variables mentioned above. 
Differences were considered statistically significant when the p value was <0.05. 
 
Results 
Among the 31 enrolled patients, five were excluded from the subsequent analyses 
because they had an attack during the hours after the recording session. Therefore, 
the final dataset consisted of 26 patients (Fig. 1). 
 
 
Fig. 1 Flow chart showing the number of included/excluded participants in the various stages of the study 
 
The participant demographics and clinical characteristics of the MO group are listed 
in Table 1. Assessable MEP recordings were obtained from all participants. Examples 
of MEP recordings from participants in the HV and MO groups are shown in Fig. 2. 
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Fig. 2 Trace illustrations of motor-evoked potentials (MEPs) from healthy volunteers (HVs) and patients with 
migraine without aura (MO) 
 
 
No differences in interictal RMTs or MEP amplitudes were noted between the two 
participant groups (t = 0.536, p = 0.594 and U = 305.0, p = 0.892, respectively; Fig. 3).  
 
Fig. 3 Grouped scatter-plot showing the resting motor thresholds (RMT [%]; left panel) and motor-evoked 
potential (MEP) amplitudes (right panel) in healthy volunteers (HVs) and patients with migraine without aura 
(MO) 
 
 
Spearman’s test revealed correlations between the neurophysiological parameters 
and clinical variables. In the MO group, the RMT was negatively correlated with the 
number of days since the last migraine attack (rho = -0.404, p = 0.04; Fig. 4). No other 
significant correlations were identified between the neurophysiological and clinical 
data in patients with MO. 
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Fig. 4 Correlation between the number of days since the last migraine attack and the resting motor threshold 
(RMT [%]) in patients with migraine who were between attacks 
 
 
Discussion 
Many clinical neurophysiology studies have shown that when patients with migraine 
are between attacks, their cortical responsiveness during the repetition of a series of 
stereotyped stimuli is enhanced when compared to controls. This functional brain 
abnormality has been detected in EPs for virtually all sensory modalities [3]. As 
mentioned earlier, previous single-pulse TMS studies examining motor cortex 
excitability in patients with migraine reported conflicting results. Overall, the results 
of the present study are concurrent with those of previous studies showing that the 
interictal RMTs and MEP amplitudes of patients with migraine do not differ from 
those of HVs [8–13]. 
To our knowledge, our study is the first to report a negative correlation between 
the RMT and time elapsed from the last migraine attack in patients with MO. This 
findings is consistent with previous evidence obtained with psychophysiological tests 
[24], neuroimaging techniques [25, 26], and cortical EPs [4–6] showing that during 
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the variable pain-free period between two migraine attacks, the brain of an individual 
with migraine is exposed to subtle cyclic functional changes. Indeed, at the cortical 
level, we previously observed that patients with MO and a subgroup of patients with 
migraine with visual aura associated with paraesthesia and/or dysphasia exhibited a 
strong decrease in EP amplitude habituation during the stereotyped presentation of 
visual stimuli with the passing of time from the last attack [4, 5]. The results of the 
present study revealed that the same correlation is valid for the resting excitability of 
the motor cortex in response to single-pulse TMS. This finding indicates that motor 
cortex excitability fluctuates during interictal phases; specifically, as the time elapsed 
from the last attack increases so does the motor cortex disexcitability. These results 
are in favour of a migraine cycle-dependent subtle imbalance between excitation and 
inhibition in the motor cortex. Below, we discuss the possible neurophysiological 
underpinnings of these TMS results and their relevance to migraine pathophysiology. 
TMS is a non-invasive technique that permits researchers to objectively evaluate 
the RMT and estimate motor cortex excitability [7]. At the RMT, TMS indirectly 
activates the pyramidal tracts by eliciting so-called indirect waves (I-waves), which 
result from the complex interactions among different types of cortical cells that 
discharge at a high frequency [27–29]. Modelling studies have shown that when the 
coil is placed tangentially on the scalp—as was the case here—the majority of the 
induced current flows parallel to the surface of the brain rather than perpendicular 
to the grey matter [30]. Consequently, TMS-induced horizontal current flow 
preferentially activates the horizontally oriented axons of cortical interneurons or 
cortico-cortical fibres that activate pyramidal neurons trans-synaptically (I-waves) 
instead of activating pyramidal neurons directly (D-waves). Therefore, the excitation 
threshold depends on the orientation and membrane properties of the axons 
activated by the TMS-induced electrical field, including axons of the tangentially 
oriented cortico-cortical loop fibres that modulate the excitability of the corticospinal 
output neurons. 
Among the cortico-cortical fibre systems, it is important to consider the influence 
that collateral gamma-aminobutyric acid (GABA)-ergic axons, which project from the 
somatosensory cortex, have on motor cortex excitability, as shown in animal studies 
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[31, 32] and in human studies using paired associative stimulation [33]. Moreover, it 
is well known that cortico-cortical loops, particularly in the general and 
somatosensory cortices, are strongly modulated by thalamocortical afferent fibres 
[32]. Interestingly, somatosensory lateral inhibition and thalamocortical drives are 
both involved in the pathophysiology of interictal migraine. Early somatosensory 
high-frequency oscillation bursts (detected by the appropriate filtration of common 
somatosensory evoked potentials), which reflect thalamocortical spike activity, are 
reduced in episodic migraine interictally; however, they normalise during an attack 
[34]. The microstructural correlates of these thalamic functional fluctuations were 
recently investigated in a diffusion tensor magnetic resonance study [26], which 
found that the interictal fractional anisotropy was significantly increased while the 
mean diffusivity was slightly decreased within the thalamus bilaterally. Interestingly, 
the right thalamic fractional anisotropy was positively correlated with the number of 
days since the last migraine attack, which is consistent with the results of the present 
study. Furthermore, a recent neurophysiological study [6] showed that patients with 
migraine have deficient lateral inhibition within the somatosensory cortex during the 
interictal phase; however, they show normal lateral inhibition during the attack. 
Nonetheless, the degree of somatosensory lateral inhibition is directly related to the 
somatosensory thalamocortical activity (evaluated as the amplitude of presynaptic 
high-frequency oscillations) and inversely related to the number of days elapsed since 
the last attack [6]. 
Owing to this interictal, morphofunctional thalamocortico-cortical evidence in 
patients with migraine, we postulate that the reduced thalamic control of the 
sensorimotor cortical activity and decreased degree of somatosensory lateral 
inhibition, which are both inversely correlated with the number of days since the last 
attack, could account for the observed subtle fluctuations in the RMT during the 
variable pain-free period between migraine attacks. However, whether these 
abnormalities in sensorimotor cortical activity are consequences of the 
‘thalamocortical dysrhythmia’ [35, 36] (a model theory on cyclical functional 
abnormalities in migraine) remains unknown. Regardless, in a previous study on a 
group of mixed patients and HVs, we found that inhibitory TMS-induced plastic 
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changes were inversely related to the level of thalamocortical activation [37], 
supporting the hypothesis that anomalous thalamic control could underlie the 
abnormal TMS findings in patients with migraine who are between attacks. 
Finally, we acknowledge as a possible limitation of the present study that some 
researchers observed that the RMT was not stable over days, which may have 
complicated the interpretation of values measured at one point in time [38]. 
However, this is not completely detrimental because it may further support our 
findings that cortex excitability is not stable between attacks but rather undergoes 
daily fluctuations during the so-called migraine cycle. 
 
Conclusions 
Here, in patients with MO who were between attacks, we detected a negative 
correlation between the RMT and the number of days since the last attack. Our 
results help explain the conflicting findings reported previously on the degree of 
motor cortex excitability in patients with migraine by showing that the RMT is 
strongly dependent on the phase of the migraine cycle. We propose that 
hypofunctioning of the thalamocortical loops and somatosensory lateral inhibition, 
beyond accounting for the dynamic variations in the sensory cortex habituation 
deficits, may contribute to the observed subtle fluctuations in motor cortex 
excitability in patients with migraine. We believe this occurs by influencing the 
cortico-cortical GABAergic inhibitory connections between the somatosensory and 
motor cortical areas. Further studies are needed to determine whether interactions 
among sensory and motor cortical activity under the control of thalamic nuclei are 
involved in the clinical and morphofunctional features of patients with migraine, 
including those experiencing aura or headache chronification. 
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Introduction 
Chronic migraine (CM) is characterized by headaches occurring ≥15 days per month, 
with ≥8 headache days fulfilling the criteria for migraine headaches, for at least 3 
months [1]. Every year, approximately 3% of migraineurs progress to CM [2]. 
Different factors may favour migraine chronification, including overuse of analgesics, 
ineffective acute treatment(s), obesity, and psychological factors such as depression, 
stressful life events, and specific personality traits [3]. Medication overuse headache 
(MOH) is very prevalent among patients attending specialized headache clinics and is 
associated with excessive use of acute medication drugs, defined as intake of 
analgesics or triptans on more than 15 and 10 days per month, respectively [1].  
According to the current diagnostic criteria from the International Classification 
of Headache Disorders (ICHD 3 beta), analgesic abuse is no longer an exclusion 
criterion for the diagnosis of CM. However, morphofunctional studies have shown 
that MOH patients exhibit peculiar cerebral morphological [4–6] and 
electrophysiological patterns when compared with pure CM patients (i.e., without 
medication overuse). In particular, while evidence for cortical sensitization 
(calculated as the initial amplitude increase of evoked potentials) has been observed 
in both pure CM and MOH patients in response to different sensorial stimulations [4–
6], deficient habituation―or persistent sensitization―to repetitive somatosensorial 
stimulation is exhibited by patients with MOH [4, 7, 8], but not those with CM [6]. 
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Because habituation can be considered a basic form of learning and memory [9], 
these findings suggest that the mechanisms underlying sensorimotor plasticity and 
learning processes could be dysfunctional in CM patients and depend on the co-
occurrence of medication overuse. 
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive tool used to 
modulate cortical excitability. When applied over the motor cortex, this 
neuromodulatory technique has been shown to induce pain relief in different types 
of chronic pain [10], mainly by effecting plastic changes in the motor area, whose 
extension is positively associated to pain intensity [11]. 
In normal subjects, rTMS is able to induce functional plastic changes depending 
on the number, intensity, and frequency of the stimulation pulses. In particular, high-
frequency trains (5 Hz) of rTMS have been reported to increase cortical excitability in 
the short term, while low-frequency stimulations (0.1-1 Hz) have been reported to 
decrease it [12, 13]. Because chronic pain is characterized by maladaptive plasticity 
in the motor system, studying the relationship between CM and motor cortex 
excitability could be interesting, not only to reveal the mechanisms related to 
headache chronification, but also for future therapeutic targets and interventions. 
In patients affected by episodic migraine with aura, low-frequency rTMS was 
shown to produce a paradoxical increase of intracortical facilitation in the motor 
cortex [14]. Studies investigating effects of high-frequency rTMS in patients affected 
by migraine with aura yielded different results depending on the TMS variables and 
experimental protocols. In patients, 5 Hz-rTMS on the motor cortex induced motor 
evoked potential (MEP) facilitation when the stimulation was delivered at an intensity 
of 110% resting motor threshold (RMT) and paradoxical MEP inhibition when 
delivered at 130% RMT [15]. In patients with episodic migraine without aura, Conte 
and co-workers [16] found that 5 Hz-rTMS, delivered at 120% RMT, induced 
abnormally high MEP facilitation. Moreover, in patients affected by migraine without 
aura, MEP response to trains of high-frequency rTMS yielded different effects 
depending on the phase within the migraine cycle, and on the frequency of migraine, 
with a physiological increasing response in the interictal phase and paradoxical 
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decremental response in both episodic migraineurs recorded ictally and in CM 
patients [17].  
To the best of our knowledge, no studies to date have performed a detailed 
examination of short-term plasticity mechanisms of the primary motor cortex 
individually in CM and MOH patients. The goal of the current study, therefore, was 
to use both low- and high- frequency rTMS over the motor cortex to identify 
distinctive neurophysiological mechanisms underpinning learning and plasticity in 
individuals with CM or MOH compared with normal subjects. 
 
Material and Methods 
Subjects 
Among consecutive patients attending the authors’ headache clinic, 40 provided 
informed consent to participate in the study, of whom 8 were excluded because they 
did not fulfil the inclusion criteria. Participants were included if they were between 
18 and 65 years of age and had at least a 1-year clinical history of migraine. 
Participants were excluded from the study if they were regularly taking medication 
(e.g., antibiotics, corticosteroids, antidepressants, benzodiazepines, or prophylactic 
migraine medication) during the 3 months preceding the study, except for 
contraceptive pills (taken by 3 HV, 2 CM, and 2 MOH). Individuals with a history of 
other neurological disorder(s), systemic hypertension, diabetes or other metabolic or 
autoimmune disease, or any other type of primary or secondary headache, were also 
excluded. Patients did not always experience the headaches on the same side. All 
participants received a complete description of the study and provided written 
informed consent. The study was approved by the local ethics review board and was 
conducted in accordance with the Helsinki Declaration. 
According to the inclusion/exclusion criteria, the final dataset comprised 32 
patients (Table 1), of whom 16 were diagnosed with de novo CM (IHCD-IIIb code 1.3), 
with no history of medication overuse, and 16, with de novo MOH (ICHD-IIIb code 
8.2), who never underwent a detoxification program during their first screening visit. 
The inclusion criteria were restricted to MOH patients overusing non-steroidal anti-
inflammatory drugs (NSAIDs) only (IHCD-IIIb code 8.2.3), because it has been 
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demonstrated in a previous study that these patients exhibit the most pronounced 
abnormalities at the sensorimotor system level compared with MOH patients 
overusing anti-migraine-specific (triptan) acute medication [4, 18]. Before 
progressing to MOH, all patients had a clear-cut history of episodic migraine without 
aura (ICHD-IIIb code 1.1). Except for 4 patients who had mild headache (mean visual 
analogue scale score 4/10), all patients underwent the MEP recordings in a pain-free 
state. Because MOH patients tend to take acute medications compulsively and 
frequently during the day, it was impossible to prevent them from taking medication 
on the day of recordings. It was managed, however, to perform the recordings at 
least 3 h after the last medication intake. For comparison, MEP trains were recorded 
in 16 healthy volunteers (HVs) with comparable age and sex distribution (Table 1), 
and no personal or familial history (first- or second-degree relatives) of migraine and 
no detectable medical condition. To avoid variability due to hormonal changes, 
female participants were examined outside their pre-menstrual or menstrual cycles. 
 
Table 1. Demographic characteristics of study participants and headache profiles of patients. Data expressed 
as mean                                                                       SD. HV: healthy volunteers; CM: chronic migraneurs; MOH: 
medication overuse headache patients; n: number of subjects. 
  HV (n = 16) CM (n = 16) MOH (n = 16) 
 Women (n) 12 12 13 
 Age (years) 32.1 ± 10.2 31.1 ± 10.2 34.4 ± 11.6 
 Duration of history of migraine (years)  13.5 ± 10.3 16.5 ± 9.2 
 Days wit headache/month (n)  22.6 ± 6.4 20.4 ± 6.9 
 Severity of headache attacks (0-10)  6.9 ± 2.2 8.1 ± 1.6 
 Nausea/vomiting (n)  13 16 
 Photophobia (n)  15 14 
 Phonophobia (n)  13 14 
 Pulsating (n)  13 14 
 Duration of chronic headache (years)  22.7 ± 24.6 18.1 ± 14.9 
 NSAID tablet intake/month (n)  32. ± 3.8 27.8 ± 13.7* 
*p< 0.001 vs. CM. 
 
 
TMS procedures 
During TMS, patients were seated in a comfortable armchair and asked to remain 
fully relaxed with their eyes closed to ensure similar attention levels. TMS was 
delivered through a high-frequency biphasic magnetic stimulator (MagstimRapid, 
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The Magstim Company Ltd., Whitland, South West Wales, United Kingdom), which 
was connected to a figure-of-eight coil with a maximal output of 1.2 T. First, the 
optimal orientation and position of the coil (i.e. ‘hot spot’) over the left motor area 
for stimulating the first dorsal interosseous muscle were determined. Thereafter, the 
RMT was identified using single TMS pulses; complete relaxation of the first dorsal 
interosseous (FDI) muscle was verified by the absence of electromyographic (EMG) 
signals, both visually (on a monitor) and by acoustic feedback. The RMT was defined 
as the minimal intensity required to elicit an EMG response of at least 50 μV with 50% 
probability in a fully relaxed muscle. Because all of the enrolled participants were 
right-handed, and because patients did not always experience the headaches on the 
same side, rTMS trains were only delivered over the left motor cortex. EMG activity 
in the right FDI muscle was recorded through surface electrodes placed over the right 
FDI muscle. Thereafter, 10 consecutive trains of 10 single pulses of TMS (stimulus 
intensity, 120% of the RMT; inter-train interval, 1 min) were delivered at a frequency 
of 1 or 5 Hz in two separate sessions (intersession interval of at least 1 week) 
performed in random order. The resulting EMG activity was filtered (bandwidth 20 
Hz–1 kHz). All recordings were collected in 3 h period between 09.00 am and 12.00 
pm by two investigators (C.L., C.C.). The 10 trains of 10 stimuli were averaged, then 
numbered anonymously and analysed off-line in a blind manner by one investigator 
(F.C.). The peak-to-peak MEP amplitudes (V) of each of the 10 responses were 
measured within the train of 10 stimuli.  
 
Statistical analysis 
Data were statistically analysed in a blinded manner by a single investigator (G.C.) 
using Statistica version 8.0 (StatSoft Inc., Tulsa, USA) for Windows (Microsoft 
Corporation, Redmond, WA, USA).  
Data were first analysed using the Kolmogorov-Smirnov to test for normal 
distribution. Preliminary descriptive analysis revealed that some the 10 MEP peak-to-
peak amplitudes within the rTMS trains had a non-normal distribution. After log 
transformation (log10[x]), all data achieved normal distribution (Kolmogorov-
Smirnov test, p > 0.05).  
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A repeated measures analysis of variance (rm-ANOVA) was performed using the 
between-subject factor ‘group’ (HV, CM, MOH) and the within-subject factor was 
‘stimuli’. To investigate the interaction effect, the two models of rm-ANOVA were 
followed by univariate ANOVA. Moreover, to quickly evaluate MEP amplitude trends 
within trains of rTMS stimuli, the slope of the linear regression line was calculated for 
the 10 stimuli for each participant on the normalized data. To analyse the slope of 
the linear regression, an ANOVA model with the between-subject factor ‘group’ (HV, 
CM, MOH) was used; post hoc Tukey honest significant difference tests were also 
performed.  
A one-way ANOVA test was used to compare the clinical and neurophysiological 
(RMT, 1st amplitude MEP) variables at baseline. Pearson’s coefficient was used to test 
for correlations between neurophysiological (1st MEP amplitude, MEP amplitude 
slope) and clinical variables (disease duration, days with headache, visual analogue 
scale score, monthly tablet intake, duration of the chronic phase, duration of the 
overuse phase). P values < 0.05 were considered statistically significant. 
 
Results 
Basic clinical and neurophysiological parameters 
Assessable rTMS trains of MEPs were acquired from all study participants. The patient 
groups exhibited similar clinical features except for the mean monthly tablet intake 
(Table 1), which was clearly higher in MOH than in CM patients (p < 0.001). The RMT 
and the 1st MEP amplitude were not significantly different between groups at both 1 
and 5 Hz rTMS (Table 2).  
 
Effects of rTMS on neurophysiological parameters 
In the rm-ANOVA model using the rTMS 1 Hz MEP peak-to-peak amplitude as the 
dependent variable, the multivariate test was significant for the factor ‘stimuli’ (F9,405 
= 5.220, p < 0.001), but not for the factor ‘group’ (F2,45 = 0.892, p = 0.417) and for the 
‘group’ × ‘stimuli’ interaction effect (F18,405 = 0.589, p = 0.907) (Figure 1 [left panel). 
As confirmation, the slope of the linear regression of MEP amplitudes over all stimuli 
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was not significantly different between groups (F2,45 = 0.726, p = 0.489) (Figure 2 [left 
panel]). 
In the rm-ANOVA model using the rTMS 5 Hz MEP peak-to-peak amplitude as the 
dependent variable, the multivariate test was not significant for the factors ‘stimuli’ 
(F9,405 = 1.535, p = 0.133) and ‘group’ (F2,45 = 0.085, p = 0.918), but it reached statistical 
significance for the ‘group’ × ‘stimuli’ interaction effect (F18,405 = 2.846, p < 0.001) 
(Figure 1 [right panel]). The slope of the linear regression of MEP amplitudes over all 
stimuli was significantly different between groups (F2,45 = 6.11, p = 0.004) (Figure 2 
[right panel]). A post-hoc analysis revealed that the slope of MEP amplitudes from 
stimulus 1 to 10 calculated in the MOH patient group (- 0.021) was significantly 
different from that calculated in HVs (+ 0.010, p = 0.001) and in CM patients (- 0.003, 
p = 0.047) (Table 2 and Figure 2 [right panel]). 
In CM patients, the mean severity of migraine assessed according to visual 
analogue scale correlated negatively with the slope of the linear regression of MEP 
amplitudes recorded in response both to 1 Hz (r = - 0.507, p = 0.045) and to 5 Hz (r = 
- 0.637, p = 0.008) rTMS trains. Whereas in MOH patients, the duration of the overuse 
phase correlated negatively with the slope of the linear regression of MEP amplitudes 
recorded in response to 5 Hz rTMS trains (r = - 0.506, p = 0.045). No other significant 
correlation between neurophysiological and clinical variables was observed in either 
group. 
 
Table 2. Transcranial magnetic stimulation (TMS) resting motor thresholds (RMT) and motor evoked 
potential (MEP) first amplitude (Log transformed) and slope of the linear regression line from the first to 
the 10th stimulus of the train. Data expressed as mean                                                                       SD. HV: 
healthy volunteers; CM: chronic migraine patients; MOH: medication overuse headache patients; n: 
number of subjects. 
  HV (n = 16) CM (n = 16) MOH (n = 16) 
 1 Hz repetitive TMS train    
      RMT (%) 54.9 ± 11.3 55.0 ± 12.6 53.6 ± 6.4 
      First MEP amplitude 2.2 ± 0.3 2.3 ± 0.5 2.5 ± 0.4 
      MEP slope -0.002 ± 0.015 -0.005 ± 0.017 -0.009 ± 0.017 
 5 Hz repetitive TMS train    
      RMT (%) 54.6 ± 11.4 54.0 ± 11.5 54.2 ± 6.4 
      First MEP amplitude 2.3 ± 0.3 2.3 ± 0.5 2.4 ± 0.4 
      MEP slope 0.010 ± 0.031 -0.003 ± 0.027 -0.021 ± 0.0.16* 
*p< 0.05 vs. CM and HV. 
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Figure 1. Motor evoked potentials (MEP) elicited by repetitive transcranial magnetic stimulation trains delivered 
at 1Hz (left panel) and 5Hz (right panel) at 120% resting motor threshold in healthy volunteers (HV), chronic 
migraine (CM), and medication overuse headache (MOH) patients. 
 
 
Figure 2. Bar charts representing the motor evoked potential (MEP) amplitude slope of the linear regression line 
from the first to the 10th stimulus of the 1Hz (left panel) and 5Hz (right panel) train of stimuli in healthy volunteers 
(HV), chronic migraine (CM), and medication overuse headache (MOH) patients (*p<0.05 MOH vs. HV and CM). 
 
 
Discussion 
The main finding of this study was that the mechanisms of short-term synaptic 
potentiation―but not depression―in the primary motor cortex of patients affected 
by MOH are different from those in HVs and pure CM patients. In fact, whereas 1 Hz-
rTMS induced similar effects in the 3 groups, causing  a decrease in M1 excitability, 5 
Hz-rTMS led to MEP facilitation in normal subjects, while having a paradoxical 
inhibitory effect in MOH patients (with a significantly different slope of MEP 
amplitudes from that calculated in HVs and pure CM patients). We discuss the 
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possible neurobiological underpinnings of these data on motor cortex excitability in 
CM and MOH and their relevance to their pathophysiology. 
In healthy subjects, rTMS at a frequency of 5 Hz with an intensity above RMT was 
shown to increase MEP magnitude and to induce a post-train facilitation up to 4 min 
[19]. This facilitation occurs at the cortical level and the mechanism involved is not 
completely clear because the output from corticospinal cells depends on the sum of 
all inhibitory and excitatory inputs to the pyramidal cells. Using 5 Hz-frequency rTMS 
at different stimulation intensities, several studies have reported an increase in 
cortical silent period duration within the stimulation train [20] and a decrease in 
intracortical inhibition both within train and post-train [21]. The latter finding is 
consistent with the reported effects of high-frequency rTMS in increasing MEP 
magnitude, because the down-regulation of inhibitory inputs is expected to result in 
increased excitability. Pharmacological studies performed to characterise the 
plasticity underlying this process reported that rTMS-induced facilitation is 
distinguished by a specific pharmacological profile suggesting a short-term 
potentiation mechanism and particularly a post-tetanic potentiation (PTP) [22]. PTP, 
which is a N-methyl-D-aspartate-receptor independent mechanism, was shown to be 
sustained by presynaptic processes including an increased spontaneous release of 
neurotransmitters and increased calcium influx [23]. This is consistent with studies 
reporting that short-lasting MEP facilitation, induced by 5 Hz rTMS, mainly depends 
on presynaptic mechanisms of glutamatergic neurotransmission [15, 16, 20].  
In our MOH patients, we found a paradoxical decrease―instead of a normal 
increase―in MEP amplitude during 5 Hz rTMS trains despite a physiological decrease 
in response during 1 Hz rTMS trains. This paradoxical pattern may reflect either an 
increase in GABAergic or a reduction in presynaptic glutamatergic excitatory 
neurotransmissions. One possible explanation for this phenomenon could be the 
homeostatic plasticity of the human motor cortex. In a hyper-excited cortex high-
frequency rTMS could facilitate the activation of homeostatic inhibitory mechanisms 
aimed to maintain cortical level of excitability within a physiological range and 
stabilize the properties of neural networks [24]. However, this homeostatic 
mechanism would be engaged only in presence of a hyper-excitable motor cortex. 
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The 1st MEP amplitude block in our MOH patients did not differ from that of HV and 
CM patients. Therefore, this mechanism cannot explain our results.  
Interestingly, the MEP amplitude slope of the linear regression line in MOH 
patients was not only significantly different from that of healthy subjects, but also 
from that of pure CM patients, indicating that the mechanisms of short-term synaptic 
plasticity are different in the two groups of patients. We noticed a trend toward a 
decrease in cortical excitability during 5 Hz rTMS in CM patients, but we failed to 
show a significant difference in MEP amplitude slope between CM and HVs. In 
contrast to the present results, the results of the study by Cosentino et al [17] showed 
that MEP amplitudes significantly decreased during high-frequency trains in patients 
affected by CM when compared to those in healthy subjects. The difference in the 
reported results could be explained by the different experimental protocol and TMS 
apparatus we used and the clinical differences in the patients between the two 
studies. In fact, we used 10 trains of 10 stimuli with a 1 min inter-train interval, 
instead of 6 trains of 10 stimuli with a 2 min inter-train interval used in the study by 
Cosentino et al [20], and we considered CM patients with a shorter mean duration of 
history with the disease (13,5 years versus 21,7 years). Moreover, the different 
magnetic stimulator and coil used by Cosentino et al (Cadwell High Speed Magnetic 
Stimulator) could account for different effective stimulation intensities. Furthermore, 
our criteria for MEP behavioural assessment differed because we considered the 
slope of the linear regression of MEP amplitudes over all stimuli, while Cosentino et 
al [17] classified responses as ‘‘facilitatory’’ or “inhibitory”, in which at least 6 of the 
MEPs were larger or smaller in amplitude than the first MEP, respectively.  
One possible explanation for the different outcomes in response to high-
frequency rTMS trains between CM and MOH patients may be that they exhibit 
different habituation responses to repetitive stimulations. In fact previous studies 
have shown that pure CM patients exhibit a normal habituation pattern to 
sensorimotor stimulation(s) [6] (which is similar to healthy subjects), while MOH 
patients exhibit a habituation deficit [4, 25], although both groups of patients exhibit 
an initial response sensitization [4, 6, 25]. The latter evidence implies that the 
neurobiological mechanisms that may differentiate the brain response in CM and 
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MOH patients are not related to a central sensitization process because it is a general 
mechanism of pain chronification, but to a factor able to set delayed behavioural 
response plasticity. Habituation represents a basic form of learning and plasticity; 
therefore it is not surprising that mechanisms underlying neural plasticity and 
learning processes could be differentially modulated depending on the co-occurrence 
of external neurobiological factors such as the clinical features and behaviour of 
patients 
This interpretation is supported by the correlation analysis. In CM patients, the 
mean severity of migraine was negatively correlated with the slope of the linear 
regression of MEP amplitudes recorded in response both to 1 Hz and to 5 Hz rTMS 
trains. This supports our argument that short-term plasticity of the motor cortex is 
positively influenced by the severity of chronic head pain, as already observed in 
other chronic painful conditions [11]. 
The same correlation was not observed in MOH patients. They showed a peculiar 
neurophysiological pattern that was proportional to the duration of the overuse 
phase, such that the greater the decreasing response during 5 Hz rTMS trains, the 
higher the duration of the overuse headache. Interestingly, previous studies have 
shown that the association between the duration of medication overuse and  
neurophysiological properties in the brain of MOH patients is influenced by genetic 
factors [25, 26]. Overall, these data reinforce the concept of MOH as a bio-
behavioural disorder in which chronic headache is the result of a co-occurrence of 
biologically inherited, behavioural and environmental (i.e., medication overuse) 
factors.  
A limitation of the present study was the lack of a detailed examination of short-
term plasticity mechanisms in the primary motor cortex in CM and MOH patients. 
Furthermore, it would be interesting to compare motor cortex plasticity in chronic vs. 
episodic migraine patients; however, this study focused on chronic migraine. This is 
because our objective was to provide insights about modifications in motor cortex 
plasticity in relation to different chronification mechanisms. Another, 
methodological, limitation of the present study was that we only stimulated the right 
hemisphere in all subjects, as we assumed that, in patients with non-fixed side of 
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headache, the mechanisms of short term plasticity are shared between the right and 
left motor cortices. Finally we did not administer a specific questionnaire relating to 
depression, even though there is evidence that depression may affect neuroplasticity 
[27]. 
 
Conclusions 
Our study demonstrates that the mechanisms of short-term plasticity induced by 
high-frequency rTMS are dysfunctional in MOH patients when compared with pure 
CM patients and HVs. The evidence of different plastic behaviour in the two groups 
of patients may indicate that MOH and CM―despite exhibiting a similar 
phenotype―exhibit different neurophysiological learning processes, probably 
related to different pathophysiological mechanisms of migraine chronification and 
that chronic exposure to non-steroidal anti-inflammatory drug use could cause 
modifications in short-term plasticity mechanisms. 
Further studies are needed to understand whether pharmacological interventions 
or medication withdrawal are able to reverse the dysfunctional plasticity to a normal 
state and to reveal whether modifications of cortical excitability using non-invasive 
stimulation techniques are able to promote this process and induce clinical benefit. 
Finally, assessing brain excitability in migraine is limited by exploring only one of the 
aspects of a more complex picture of abnormal cortical excitability; therefore, future 
studies should combine different neurophysiological techniques to explore different 
pathophysiological aspects of migraine chronification.  
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